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  context: genetics services in new ZealanD
.  introduction
Genetic testing of minors does not attract special regulation in New Zealand.1 
Indeed, genetic testing services in general attract no special regulation. There appears 
to be no nationally cohesive strategy in terms of genetics services delivery, despite 
a number of reports and recommendations from the National Health Committee 
(NHC) over the last ten to fifteen years calling for a national strategy and greater co-
ordination of primary, secondary and tertiary services in the area.2 There is no clear 
Ministry of Health policy on genetic testing services generally, let alone in respect of 
carrier testing, predictive testing, susceptibility testing or genetic testing of minors 
in particular. 
.2  national health committee report 200
In 2003 the NHC released a report, Molecular	 Genetic	 Testing	 in	 New	 Zealand, 
identifying risks for New Zealand associated with the expected increase in demand 
for genetic testing as genetic knowledge develops.3 The report was critical of the state 
of genetics services in New Zealand. 
The NHC was concerned about the lack of oversight and co-ordination of genetics 
services delivery. The report made many recommendations relating to the assessment 
and evaluation of new genetic tests; quality in laboratory and clinical services; and 
practitioner and consumer issues. The NHC also expressed concern that clinical 
genetics services in New Zealand were not sufficiently well resourced to meet the 
expected increase in demand (partly arising from increasing interest in predictive 
testing). The number of clinical geneticists and genetic counsellors in New Zealand 
fell well short of international standards, and there were no pathways to increase 
capacity. ‘Unless there are sufficient trained clinical geneticists and genetic associates, 
there will continue to be inequitable access to safe genetic testing and this inequity 
will grow.’4 
The report summarised the risks for practitioners and consumers of increased public 
demand for a range of genetic tests: 
Inadequate delivery of genetic testing services due to:
a. underresourcing
b. shortage of specialist clinical geneticists and genetic associates
c. patients accessing specific genetic tests from health professionals outside clinical 
genetics services, some of whom may have a limited knowledge of genetics, the 
complexities of genetic testing, and its implications
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d. insufficient support for health professionals outside clinical genetics services as 
the technology develops
e. the variable ability of health professionals to deliver culturally appropriate 
services and services which meet the needs of people with disabilities in the area 
of genetic testing.5 
The report placed much emphasis on practitioner and consumer safety. It recognised 
that the increase in demand for genetic testing would mean that more general 
practitioners (GPs) would be involved in genetic testing. The NHC recommended 
that GPs, specialists and medical students have increased access to genetic education. 
It also suggested that more sensitive or controversial genetic testing, such as carrier 
testing and predictive testing, be co-ordinated through genetics services. Inappropriate 
ordering of genetic tests was apparently widespread, and there was no scrutiny for 
inappropriate ordering where test requests did not go through genetics services.6 
The report noted that it was difficult to build capacity, and to ensure consistency of 
service provision, access to services and the dissemination of information to, and 
education and training of, health professionals involved in genetic testing outside the 
clinical genetics services, when services were regionally based and co-ordinated.7
Regardless of whether the Ministry of Health implemented a nationally co-ordinated 
genetics services programme, the NHC noted that protocols were urgently required 
to assist practitioners to assess when and how different genetic tests should be used. 
As an example, predictive genetic testing for disorders such as Huntington disease 
(HD) would be handled through genetics services only. The NHC recommended: 
•	 Protocols be developed for each test approved for use and, distinguishing 
between diagnostic, carrier, and prediction or predisposition testing, include:
	 −	 consent protocols
	 −	 when and how each test should be used
	 −	 which practitioner has access to which genetic test based on education and  
 training
 − the appropriateness of the use of each test for children [emphasis added] 
	 −	 sensitivity to cultural issues and in particular, to the needs and expectations  
 of Mäori as tangata whenua
 −	 appropriate levels of support in decision-making for those whose decision- 
 making may be compromised such as those with sensory or intellectual   
 disabilities
•	 a process be devised for the development of such protocols including 
involvement from medical geneticists, other health professionals, consumer 
groups, and disabled people’s organisations.8
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The NHC contended that:
Protocol	development	would	address	the	inappropriate	ordering	of	genetic	tests	
and	lack	of	confidence	of	primary	healthcare	practitioners	to	provide	adequate	
information	 and	 to	 know	 when	 to	 refer.	 The	 committee	 would	 favour	 this	
approach	over	regulation.9	
Such protocols have not been developed.
The NHC also recommended that ‘ways of making information about genetics more 
accessible to the public be investigated, including information about the limitations 
of genetic testing’,10 particularly in relation to predictive testing. It was suggested that 
the public needed access to sources of information other than medical practitioners. 
The report discussed genetic testing of minors only briefly, noting that consent issues 
made genetic testing even more complex. They noted that children and young people 
should be involved in such decisions, but that their best interests were ‘the bottom 
line’. The NHC commented that genetic testing of children for untreatable late-onset 
disorders may not be in their best interests. However, with regard to the tension 
between children’s rights and the parents’ ‘need’ to know whether their children were 
likely to become ill, the NHC contended that parents have a legal right to consent to 
genetic testing on behalf of their children. 





The report states that many adults choose not to undergo predictive testing for 
late-onset conditions, and that testing children ‘eliminates the possibility of future 
autonomous choice, risking stigma and discrimination’.12 The NHC observed that 
the American Academy of Pediatrics considered predictive testing of minors for 
untreatable late-onset disorders to be inappropriate, and concurred with the view 
that ‘parents must be fully informed of the potential for harm including psychological 
damage, stigmatisation and discrimination’.13
The NHC generally recommended against genetic testing of minors, except for early 
onset conditions or those  for which beneficial medical interventions are available 
in childhood. The report does not mention any of the other professional position 
statements in respect of genetic testing of minors, or how to approach competent 
minors’ requests for genetic testing. 
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.  genetics services
Specialist clinical genetics services in New Zealand are provided by the Northern 
Regional Genetics Service and the Central and Southern Regional Genetics Service. 
The Northern Regional Genetics Service is based in Auckland and administered by 
the Auckland District Health Board (DHB),14 and provides services to the central and 
upper North Island. The Central and Southern Regional Genetics Service is based at 
Wellington Hospital and administered by Capital Coast DHB. It also has an office 
in Christchurch, and provides services to half of New Zealand’s population: in the 
geographic region from New Plymouth to Invercargill.15 The Central and Southern 
Regional Genetics Service co-operates closely with the genetic testing group within 
the molecular pathology laboratory of Canterbury Health Laboratories ‘to provide a 
comprehensive clinical and molecular genetics service to patients and clinicians over 
the South Island and lower North Island’.16 There is also a clinical geneticist based 
in Dunedin.
Most molecular genetic testing undertaken in New Zealand is for rare heritable 
monogenic or chromosomal disorders, and carrier testing.17 The clinical genetics 
services are also used for genetic diagnoses and particularly for harder to source 
genetic tests. Clinical genetics services sometimes take referrals from other health 
professionals, and are sometimes contacted directly by families.18 
Genetic tests are ordered by clinical geneticists, and also by GPs, paediatricians, 
physicians, obstetricians and neurologists.19 Currently, predictive and carrier testing 
are most likely to be undertaken within a clinical genetics service.20 
However, any genetic test can be ordered by any medical practitioner, and primary 
and secondary care practitioners are increasingly being asked for genetic tests by 
their patients. Some referrals for genetic testing of children (primarily symptomatic) 
are made by primary and secondary health-care professionals, including GPs and 
paediatricians. 
Informal	 communication	 with	 genetic	 laboratories	 showed	 that	 the	 majority	




DHB laboratories ‘tend to carry out more complex tests including the majority of 
genetic tests’22 and must be accredited by International Accreditation New Zealand 
(IANZ).23 Laboratories involved in genetic testing must also comply with the 
National Pathology Accreditation Advisory Council (NPAAC) guidelines.24 Research 
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laboratories are not required to be IANZ accredited,25 although they may provide 
genetic testing on a research basis. 
The two main professional organisations involved with quality assurance for genetic 
tests in New Zealand are the Royal College of Pathologists of Australasia (RCPA) and 
the Human Genetics Society of Australasia (HGSA).26
District Health Board laboratories have their own protocols regarding certain 
types of genetic tests, stipulating that specimens for some disorders, such as 
adrenoleucodystrophy (rare inherited disorder causing a progressive loss of physical 
and mental skills),27 Huntington disease, familial breast cancer and hereditary non-
polyposis colorectal cancer, will not be analysed without evidence that full risk 






For	 carrier	 testing	 and	 prenatal	 diagnosis	 the	 patient	 must	 have	 undergone	
proper	 counselling	 through	 the	 established	 national	 protocol	 for	 Huntington	
Disease	Testing.	…	Referral	reason	plus	adequate	information	and	family	history	
must	be	submitted	with	the	specimen.	...30
LabPLUS (which includes the Auckland DHB molecular genetics laboratory) also 
states that ‘Medical genetic consultation is available to complement all requests for 
DNA analysis and is particularly indicated in complex cases or in situations where 
the diagnosis is atypical or uncertain.’31 
These protocols are in accordance with the HGSA policy, Presymptomatic	and	Predictive	
Testing	 for	 Genetic	 Disorders,	 which recommends that ‘Laboratories that perform 
predictive tests should develop protocols in consultation with the multi-disciplinary 
team governing the conditions under which samples are accepted for testing.’32 
The World Health Organisation (WHO) has also noted that genetic testing requests 
in New Zealand ‘are reviewed as they come into the laboratory for appropriateness 
… thus control of testing is at the laboratory level’.33
Internal	policies	have	been	set	by	the	Auckland	Diagnostic	Genetics	Department	




When a laboratory that performs genetic testing receives a request for a predictive 
genetic test, which has not been referred through a genetics service, the request 
would usually be followed up by the pathologist. The pathologist may call the health 
professional who ordered the test to clarify the situation and the reasons for testing, 
among other matters.35 Thus inappropriate referrals for genetic testing may be 
detected at the pathology stage. 
Wertz and Reilly have commented that:
Although	 laboratories	 may	 not	 regard	 themselves	 as	 policy	 makers	 or	 as	 gate	
keepers,	 they	 are	 responsible	 for	 informing	 physicians	 who	 order	 tests	 about	
the	 technical	appropriateness	of	a	 test.	 ...	They	can	help	 to	educate	physicians	
(including	 the	 growing	 number	 of	 primary-care	 physicians	 who	 order	 genetic	
tests)	about	the	medical	appropriateness	of	the	testing	of	children	of	various	ages.	
…	Some	doctors	may	turn	to	laboratories	for	guidance.	In	our	study,	18	per	cent	
of	 the	 laboratories	 reported	 that	 physicians	 had	 consulted	 them	 about	 ethical	
issues	involved	in	the	testing	of	children.36
.  genetic counselling 
Evidence of genetic counselling is mandatory before laboratories will perform some 
predictive and carrier tests (see examples above).
The HGSA explains that:











Genetic counselling is undertaken ‘by a team of health professionals, which may 
consist of clinical geneticists, genetic fellows, genetic counsellors, associate genetic 
counsellors, fetal medicine specialists, oncology specialists and social workers’.38 
Genetic counsellors or genetic associates, as they are often called in New Zealand, are 
attached to the genetics services. They are tertiary trained, with specialist postgraduate 
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training in genetics and counselling, and are certified by the HGSA to provide genetic 
counselling in conjunction with a clinical geneticist.39 
Individuals	undergoing	genetic	 testing	within	genetic	 services	 in	New	Zealand	






There is a shortage of both clinical geneticists and genetic counsellors in New 
Zealand. The minimum requirements would perhaps be met by having eight 
clinical geneticists and the same number of genetic counsellors for New Zealand’s 
population of 4.2 million. The reality of current staffing levels falls well short of the 
recommendations.41 
Given that primary and secondary health-care professionals are able and apparently 
willing to make referrals for genetic tests, and the evidence that many GPs have a lack 
of knowledge about medical genetics (discussed under the heading ‘Surveys of GPs’ 
knowledge, attitudes and practice regarding genetic testing’), some individuals may 
not be receiving appropriate or effective genetic counselling, or any genetic counselling 
at all, when they are not dealt with through the genetics services. Indeed, as genetic 
testing becomes increasingly common, particularly in the primary health-care 
sector, the time and resources available for genetic counselling may correspondingly 
decrease; for more straightforward testing scenarios genetic counselling may simply 
involve handing over an information pamphlet.42
.  surveys of gPs’ knowledge, attitudes and practice regarding genetic testing
It	is	inappropriate	for	all	health	practitioners	to	be	expected	to	order	all	genetic	
tests,	 given	 the	 level	 of	 knowledge	 required	 for	 adequate	 informed	 consent	
processes.43	
Genetic	 testing	 technology	 has	 rapidly	 advanced	 and	 become	 more	 widely	





A 2002 report for the NHC found that ‘much genetic testing is carried out outside of 
genetic services by both primary care practitioners and by medical specialists’.45 The 
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report expressed concern that ‘lack of knowledge on the part of some non-genetic 
clinicians may impede the quality of services received by individuals outside specialist 
genetic services’.46
Two empirical studies have been conducted with GPs (and other groups) in New 
Zealand seeking to establish their attitudes, knowledge and practice regarding genetic 
testing.47
1.6.1  The 2003 study for the NHC
The NHC commissioned a survey of 600 GPs in 2003 to find out current practice 
and training needs in respect of heritable genetic disorders. Responses were received 
from 328 (56 per cent) of the 586 eligible GPs.48 The survey revealed that many GPs 
had little experience or knowledge of less common genetic conditions and a lack of 
confidence about when to refer and to whom. Most of the respondents felt that they 
needed to know more about genetic testing to feel confident to deal with increasing 
public demand, including knowing when and for what conditions to refer a patient 
to genetics services, and how to discuss genetic tests and test results with patients.49 
The majority of respondents (132 or 70.4 per cent) had ordered one or more genetic 
tests for haemochromatosis (chronic disorder involving the excessive absorption and 
inappropriate storage of iron)50 in the past twelve months. However, very few had 
ever ordered a genetic test for HD (twenty-one, or 5.9 per cent) or for myotonic 
dystrophy (the most common adult form of muscular dystrophy)51 (eight, or 2.2 per 
cent).52 Responses indicated that GPs tended to be more likely to refer patients to 
genetics services than to order genetic tests themselves. 
GPs were presented with three clinical vignettes, relating to breast cancer, HD and 
cystic fibrosis. They were questioned as to risk factors for the three conditions, steps 
they would take if the patient were significantly at risk, consent requirements, type 
of genetic testing available, attitude as to benefits of testing, confidence in discussing 
test results and implications of test results for the patient and his or her family.
The responses to all three scenarios indicated ‘limited knowledge of genetics and the 
appropriate terminology and procedures’.53 Many GPs felt that they needed further 
information or advice before they would feel confident discussing genetic test results 
with their patients, particularly in respect of breast cancer and HD. The authors note 
that there are currently no guidelines available to assist GPs in New Zealand with 
decisions around when to refer patients, the conditions they should be referring and 
how to access tests and explain tests and test results.54 
GPs indicated that their rarity made it particularly difficult for them to keep up with 
developments in knowledge and treatment of some heritable conditions. ‘Even a 
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yearly information sheet would be advantageous in providing a resource for current 
practice.’55 Some, particularly rural GPs, also found genetics services difficult to 
access. A smaller number also indicated that costs and waiting time could be a barrier 
to access to genetics services.56 
‘What	 is	 clear	 though	 is	 that	 a	 substantial	 number	 of	 New	 Zealand	 GPs	 are	
not	 sure	how	to	access	genetic	advice	 for	 their	patients	and	some	reported	not	
knowing	how	to	contact	Genetics	Services	in	their	locality.57
The Report did note that GPs who had referred patients to genetics services were 
receiving good patient-specific advice from genetics services.
GPs appeared to be generally positive about getting involved in genetic testing as long 
as they had adequate resources and support. 




genetic	 information	 to	 patients,	 which	 this	 study	 found	 to	 be	 particularly	
problematic.	 However,	 more	 work	 is	 needed	 to	 validate	 these	 findings	 and	 to	
further	explore	genetic	educational	requirements	in	a	New	Zealand	context.58	
1.6.2  Attitudes regarding genetic testing for breast cancer susceptibility: GPs, medical   
 students and women
Discussing their own survey of New Zealand GPs, and other groups, Cameron et al. 
note that: 





Cameron et al. contend that ‘patients place considerable weight on the opinions of 
their doctors when making decisions about risk assessment procedures’.60 
Given	that	many	individuals	are	referred	for	genetic	testing	by	their	GPs,	these	
practitioners	 play	 a	 pivotal	 role	 as	 de	 facto	 gatekeepers	 in	 the	 genetic	 testing	




Cameron et al. undertook a survey ‘to assess attitudes about genetic testing for breast 
cancer susceptibility held by general practitioners (GPs), medical students, and 
women varying in familial risk’.62 The women’s groups were made up of patients 
recruited from the waiting rooms of seven clinics, breast cancer survivors and first 
degree relatives of breast cancer survivors. Over 75 per cent of all groups (GPs, 
medical students and the women’s groups) endorsed the idea of genetic testing for 
breast cancer susceptibility. 
For every question (relating to attitudes about health benefits, psychological benefits, 
psychological costs, discrimination, prophylactic mastectomy and prophylactic 
oopherectomy) the GPs or the medical students held less favourable views about 
genetic testing than the women’s groups.63 The authors note that this highlights ‘the 
need for doctors to be aware of potential attitudinal discrepancies with patients’.64
The medical students were more cautious than the GPs about recommending genetic 
testing, and about expecting positive outcomes. GPs were more likely to emphasise 
the benefits of testing rather than the psychological costs, in their discussions with 
patients, whereas medical students gave the two topics more equal treatment. 
There was also a positive correlation between more recent medical training and a 
greater willingness to discuss genetic testing with patients.65 Cameron et al. suggest 
that genetics education in medical school promotes greater sensitivity to genetic 
testing issues.66 This suggestion conforms with previous research findings that more 
recent medical graduates demonstrate greater knowledge of genetic testing issues 
than older graduates.67 
GPs were more likely than medical students to agree that clear guidelines for managing 
patients with positive genetic test results were lacking. The authors note that ‘there 
appears to be a need’ for genetics services to provide more information about such 
guidelines to the GPs in their regions.68
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.7  Discussion 
GPs	 still	do	not	have	much	contact	with	genetic	 testing	and	 there	will	always	
be	problems	 training	groups	of	professionals	under	 these	circumstances.	 In	 the	
context	of	the	competing	demands	of	a	busy	general	practice	workload	GPs	need	
to	 know	 how	 to	 access	 information	 about	 Genetics	 Services	 easily	 when	 the	
need	arises.	GPs	who	responded	to	this	 survey	requested	access	 to	 information	
and	suggested	guidelines	and	continuing	medical	education	sessions	as	possible	
avenues	for	the	delivery	of	information.69
It is not surprising that New Zealand’s primary health-care practitioners (and other 
non-geneticists) feel ill-prepared to deal with the existing requests and expected 
increased demand for genetic testing, given the absence of a national policy or strategy 
for genetics services delivery, or any guidelines for referral for testing or follow-up 
post-testing. Genetics services in New Zealand appear to suffer from a lack of co-
ordination and resourcing. Such disorder cannot facilitate the necessary education 
and guidance required by GPs, paediatricians and other health professionals. 
It is vital that GPs and other health professionals know more about genetic testing 
and genetics services in New Zealand so that they can better facilitate informed 
consent; recognise and acknowledge any limitations in their expertise, particularly as 
they will influence their patients when they discuss testing possibilities;70 know when 
to refer patients for genetic testing; and can offer some degree of genetic counselling, 
if required. 
Additionally, there is some concern that as genetic testing becomes increasingly 
ubiquitous in New Zealand, and increasingly dealt with by primary health-care 
professionals, genetic counselling will be inadequate or non-existent (because of 
personnel shortages and training, time and resource deficits). 
.  Progress?
The co-ordinating agency for the District Health Boards (DHBNZ) has reportedly 
recently set up an expert group ‘to prepare for the improvement to genetic services’,71 
apparently based, at least loosely, on the recommendations made in the NHC 2003 
Report, Molecular	Genetic	Testing	in	New	Zealand.
given that genetic testing of minors does not attract special regulation in  
new Zealand, or even special policy (at this stage), does it raise new issues  
that need to be considered by regulators?
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2  Does genetic testing oF minors raise new issues From   
 those involveD in other meDical Decision-making   
 contexts?
Informed	choice	for	genetic	testing	is	more	complex	than	most	other	health	related	





‘Today most persons brought into contact with a genetics clinic are children under 
the age of 14 years.’73 Given that New Zealand has no specific policy or regulation on 
genetic testing or genetic testing of minors, does this raise new issues? 
Genetic testing raises many of the same issues involved in routine medical interventions 
for minors: clinical judgment; best interests; competence; and informed consent. 
However, some commentators wish to distinguish genetic information from other 
kinds of medical information. Some have isolated arguably unique aspects of genetic 
information for policy analysis,74 although they are not all necessarily relevant to this 
discussion on genetic testing of minors.
Mason and Laurie isolate the following features as being peculiar to genetic 
information: it has implications for the blood relatives of the ‘proband’; it has 
implications for future relatives; it can disclose the likelihood of future ill-health; it is 
immutable; it has a ‘perceived benefit … in the guise of predictability’.75 
Parents generally have a wide discretion to make medical decisions in respect of 
their children, and there is evidence that parents (and others) believe that they are 
also entitled to make genetic testing decisions for their children.76 Minors who are 
competent (pursuant to legislation or the common law) to make their own medical 
decisions can presumably also give legally effective consent to genetic testing. However, 
there is considerable debate about whether certain types of genetic tests should be 
performed on minors, and about the different circumstances in which such tests may 
or may not be appropriate. In particular, it is the familial and predictive nature of 
genetic tests and test results that provide the most fertile fodder for the discourse on 
genetic testing and minors.
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2.2  Familial nature of genetic information
The familial nature of genetic information is relevant to all types of genetic testing, 
for all people – not just minors. Test results indicating a heritable genetic mutation 
in one family member invariably reveal information about the genetic risk status 
of other (and future) family members. For this reason the familial nature of the 
health information is a new issue raised by genetic testing. The familial element is 
present in all types of testing for heritable genetic disorders: symptomatic, predictive, 
susceptibility, and carrier testing. 
There are three major issues raised by the familial aspect of genetic testing, specifically 
in the case of minors:
• Genetic tests can reveal non-paternity.
• In whose interests or for whose benefit are such tests carried out on minors?
• Disclosure, confidentiality and privacy issues are complex and important.
Disclosure, confidentiality and privacy matters are particularly key issues raised 
by genetic testing of minors; these will be considered in detail, after the regulatory 
frameworks for decision-making in this area have been discussed. 
2.2.1  Genetic tests can reveal non- paternity
Genetic test results for heritable disorders may reveal information about paternity. 
Parents need to be aware that there is a possibility that non-paternity could be 
revealed as a consequence of having a child tested for a heritable genetic disorder. 
Such a possibility should not be a reason for not having a child tested where the 
test is clinically indicated as being in the child’s best interests e.g. when a child is 
symptomatic and there is effective medical management available upon confirmation 
of diagnosis. Conversely, genetic tests for heritable disorders should not be used 
primarily as a paternity test (not least because results may not be conclusive). 
The possibility of the revelation of non-paternity raises issues around disclosure of 
results, and questions about in whose interests a child might be tested. 
2.2.2  In whose interests or for whose benefit are such tests carried out (or not carried  
 out) on minors?
It is possible for parents to have their children tested for genetic disorders in order 
to learn about the genetic risks in other family members. Indeed, a family history of 
a specific genetic disorder is one of the primary reasons for seeking genetic testing. 
The more direct route to discovering another person’s genetic risk status would be 
to have the individual concerned tested, but there are situations in which this might 
not be feasible. For example, a wife may wish to discover whether her husband will 
develop HD, given that he has a family history of the disorder. Her husband may 
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refuse to have a pre-symptomatic test. The wife might seek pre-symptomatic testing 
of any child of the relationship in an attempt to find out whether her husband has 
HD. If the child is mutation-positive for HD, the father will necessarily be mutation-
positive also (presuming that the wife has no family history) and will develop HD in 
the future. (Although if the child tested negative for the HD mutation, the mother 
would still not know whether her husband had the HD mutation.)77 
Family members are not bound by any legally recognisable duties to keep family 
health information confidential,78 and thus the information from a minor’s genetic 
tests can be relayed to other interested family members. There is a converse issue also 
– some parents may	not	want a child to have a genetic test	because of the information 
that the results will reveal for other family members. For example, in the HD scenario 
posited above, the father of the child concerned might not want her to have a pre-
symptomatic test because confirmation of the gene mutation in his child would 
mean that he will develop HD. Where there are questions around the paternity of a 
child, the mother in particular may not want the child to have a genetic test. 
Perhaps the most common reason for seeking genetic testing of a minor is the desire 
for certainty. People within families that carry serious heritable genetic disorders 
are understandably anxious that their offspring may have inherited the disorder. 
For some people the benefits gained from certainty may be greater than the harms 
potentially associated with knowing that one will develop a serious disorder in the 
future.79 
Parents may want to know whether their child has or will develop a genetic disorder 
in the future for a variety of reasons not specifically related to the individual child’s 
well-being, including their own future reproductive decisions (knowing whether an 
existing child will develop a genetic disorder may assist parents in family-planning 
decisions), and facilitating open relationships within the family.80
Parental motives may be questioned in seeking genetic testing for a child, particularly 






Similarly, McLean has highlighted that if a competent child gives consent to a genetic 
test ‘the knowledge that others in the family may be affected places a heavier burden 
on the child than would knowledge of a non-heritable condition’. She asks, ‘Should 
the child share the information?’ and other questions along those lines.82 That issue 
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will not be discussed in any depth in this report because it is seen as part of the much 
wider question of whether health professionals or family members have moral or 
legal obligations to share knowledge of familial genetic risks. 
2.  the predictive nature of genetic testing 
The question of whose interests are served by genetic testing relates to one of the 
other more novel and controversial issues raised by genetic testing: predictive genetic 
testing of minors. 
Carrier testing of minors can also be considered under this heading, because the 
information gained from a carrier test can contribute to the prediction of possible 
outcomes of various reproductive choices, and for that reason is sought for the 
purposes of future reproductive decision-making. 
The predictive power of genetic information raises concerns about how genetic 
information is understood; in whose interests a minor may undergo genetic testing; 
and the best interests of the child and the child’s autonomy and future autonomy. 
Genetics is a highly specialised branch of medical science, not well understood 
even by health professionals outside of the speciality,84 let alone the general public. 
Ensuring that minors and families understand not just the clinical but also the ethical 
and potentially social and legal consequences of having a test for a genetic disorder 
is of vital importance. 
It	is	far	harder	to	explain	severe	preventative	treatment	than	to	explain	treatment	
intended	to	alleviate	or	cure	problems	which	the	child	is	already	experiencing.85
The consequences of genetic information may be more complex than other medical 
information, given its ability to predict the future health of an asymptomatic 
individual, with varying degrees of certainty. In terms of genetic testing providing some 
certainty or alleviating anxiety, there is a great deal of residual uncertainty regarding 
the interpretation of predictive genetic test results. When genetic mutations are not 
fully penetrant, and only indicate susceptibility to a disorder, the risk of developing 
the associated disorder may vary according to a number of factors e.g. the particular 
gene(s) and genetic variation(s) in question; the total genetic environment;86 and 
environmental factors. Further factors that might affect a person’s likelihood of 
developing a particular disorder remain unknown.
Given	the	complexities	 in	communicating	genetic	risk	 information,	 it	 remains	
unclear	how	well	individuals	understand	disease	risk	…87	
There is evidence that, when a heritable genetic variation that predisposes a person to 
a disorder is discovered, people do not well understand genetic risk or the probability 
of developing the disorder. 
0
Studies	 in	 the	 UK	 and	 USA	 have	 shown	 that	 women’s	 perceptions	 of	 the	
population	risk	of	cancer	and	their	personal	vulnerability	are	at	variance	with	
medical	perspectives.	Before	genetic	risk	counselling,	a	minority	of	women	have	
an	accurate	view	of	 the	 chances	of	developing	breast	 cancer,	and	 the	majority	
either	over-	or	underestimate	[9,10].	…	Genetic	risk	counselling	has	been	shown	
to	 improve	 significantly	 the	 accuracy	 of	 risk	 perception	 [10,11,12,14,15,16],	
but	up	to	30%	of	UK	women	and	two-thirds	of	US	women	continue	to	report	
exaggerated	risks	of	cancer.88	
Even if a genetic mutation is predictive or fully penetrant, the genetic test results 
cannot always, at least at this stage, predict how mild or severe the expression of the 
disorder will be in the particular person tested. There are also no guarantees as to the 
age of onset, if at all, of any of these types of conditions.
Additionally, a negative	 test result for a BRCA 1 mutation (one of the genetic 
variations associated with hereditary breast cancer), for example, does not mean 
that the person tested will never develop breast cancer. The person tested may have 
another hereditary genetic variation predisposing her to breast cancer, or she may 
develop breast cancer independently of any known hereditary factor. 
One concern about carrier testing, in particular, is that it is in a sense potentially 
more complex to explain. A carrier will not be ill, and generally there will be no 
consequences of being a carrier until reproductive decisions are to be made. There are 
exceptions; for example, female carriers of some X-linked disorders, such as fragile 
X, may be mildly affected by the disorder . However, concern remains that the mere 
fact of knowing that one is a carrier may confuse the person or result in increased 
anxiety. In their research into families at risk for Duchenne muscular dystrophy or 
hemophilia A, interestingly Jarvinen et al. found that:
Carrier	 testing	 was	 in	 most	 cases	 [65	 per	 cent]	 correctly	 understood	 and	 the	
matter	 openly	 discussed.	 Our	 results	 do	 not	 suggest	 that	 testing	 in	 childhood	
had	caused	serious	harm	to	the	young	individuals	tested.	On	the	other	hand,	we	
found	no	obvious	benefits	from	this	early	testing.89
2.  testing in whose interests? 
Parents may wish to harness the predictive power of a genetic test of their child to 
assist with the following matters, among others:
•	 Planning where to live e.g. close to medical services in cases where a child’s 
condition may be chronic;
•	 Financial planning in terms of likely medical costs and auxiliary expenses;
•	 Financial planning in terms of whether to prioritise certain things when the 
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child is young as opposed to saving for his or her future expenses (such as 
university or overseas travel).
Much of the debate about whether children should have carrier or predictive genetic 
tests revolves around whether genetic testing is in a minor’s best interests; different 
interpretations of ‘best interests’; and questions of ‘future autonomy’ and the ‘right 
not to know’.
Ryan et al. have suggested that ‘[g]enetic or clinical screening of asymptomatic people 
is contentious as no intervention has been definitively proved to alter prognosis’.90 All 
that would be ‘gained’ from such testing, on this argument, might be negative rather 
than positive. Borry et al. put the argument this way:
This	 caution	 originates	 from	 the	 fear	 that	 testing	 in	 childhood	 or	 adolescence	
could	 create	 devastating	 social,	 emotional,	 psychosocial	 and	 educational	
consequences	 in	minors.	Some	have	 suggested	 that	genetic	 testing	might	harm	
a	child’s	self-esteem,	create	depression	or	anxiety,	distort	the	family	perception	
of	a	child	or	stigmatize	a	child.	Authors	have	also	stressed	that	testing	children	
can	 breach	 the	 confidentiality	 and	 the	 privacy	 of	 genetic	 information,	 ignore	




The General Medical Council (GMC) gives pre-symptomatic testing a slightly 
warmer reception, declaring that it ‘can be an important tool in providing effective 
care’, but also cautions that ‘the uncertainties involved in screening may be great, 
for example the risk of false positive or false negative results. Some findings may 
potentially have serious medical, social or financial consequences not only for the 
individuals, but for their relatives. In some cases the fact of having been screened may 
itself have serious implications’.92 Thus, the GMC stresses the importance of ensuring 
that any purported consent is based on a truly informed decision, and that as far as 
possible health-care professionals should seek to ensure that the test is not against the 
interests of the person. 
Given that there are generally no clinical indications for testing a child for a late-onset 
disorder for which there are no available prophylactic measures or beneficial medical 
interventions, it is widely considered that such testing is against the best interests 
of the child.93 Not only is there no medical benefit to testing, but also the child may 
suffer psychological and social harm from being tested for an unpreventable and 
untreatable disease, such as HD, as a child. Additionally, the child would lose the 
opportunity to decide whether she  wanted to know about a possible increased risk 
for HD. The ‘right not to know’ that information would be lost. 
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When the outcome is neither obviously beneficial nor harmful, the question of 
whether or not the test should be offered or conducted becomes highly problematic; 
arguably the question again arises regarding for whose benefit the test is being 
conducted at all. If there is nothing urgent about the test – for example, in the case of 
carrier testing – it must surely be arguable that there is no self-regarding reason for 
the child to undertake it. Should the results be of relevance to the child, they could 
seek a test once they attain competence.
These issues, related to a minor’s best interests and autonomy, are explored in greater 
detail later in the section ‘Benefits and harms involved in genetic testing of minors’.	
2.  conclusion
The issue of genetic testing of minors is far from uncontroversial. Genetic testing of 
minors does raise new issues from those involved in other medical decision-making 
contexts. Most of the concerns relevant to minors in particular are prompted by the 
familial and predictive aspects of genetic information. Genetic testing may have far 
greater personal implications for other family members than decisions made in other 
medical contexts. Additionally genetic information has the power to be more predictive 
of future health than other medical tests or interventions, which has implications for 
the minor’s best interests and autonomy. The limited ability of genetic information 
to predict outcomes is also a source of concern: genetic information can be difficult 
to understand and its implications easily misunderstood.
We next examine how professional guidelines, attitudes and practice have responded to 
the issues raised by genetic testing of minors, before looking at whether the differences 
are legally salient and thus require new legislative or regulatory responses.
  ProFessional guiDelines anD Position PaPers in resPect  
 oF genetic testing oF minors
.  introduction
What do the various professional guidelines and position statements on genetic 
testing of minors say about testing of children who cannot give informed consent, 
and the ability of competent minors to consent to testing? We explore the relevant 
guidelines on genetic testing of minors to elucidate the professional context in which 
health professionals are making genetic testing decisions. We discuss the professional 
guidance most applicable to New Zealand health professionals and also briefly 
outline and discuss more generally other relevant guidelines and position statements 
on genetic testing of minors. 
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.2  minors who cannot give informed consent
There are no New Zealand-specific guidelines or professional position statements 
on genetic testing and minors. However, the HGSA guidelines apply to New Zealand 
health professionals involved in genetic testing.
The former New Zealand Independent Biotechnology Advisory Council (IBAC) 
(2002) document, Genetic	Testing, stated that: 
Except	 for	 the	 diagnostic	 confirmation	 of	 symptoms,	 the	 testing	 of	 children	 is	
generally	not	considered	appropriate	unless	 the	child	will	directly	benefit	 from	
the	results	of	the	test.94	
According to IBAC, direct benefit was the key criterion for testing of minors. 
Medical benefit in particular was not specified; however, the two scenarios posited 
for consideration after the quoted statement suggest that the existence of medical 
benefits was key. 
It	could	be	unnecessarily	traumatic	for	children	to	undergo	tests	for	possible	future	
disorders	 where	 neither	 clinical	 action	 nor	 substantial	 life	 style	 modification	
would	need	to	occur	before	adulthood.95
.  human genetics society of australasia, 200
The policy Predictive	Testing	in	Children	and	Adolescents	2005	is	to be read 
inconjunction with	Presymptomatic	and	Predictive	Testing	for	Genetic	Disorders	
2005.
Among other goals, the HGSA aims to promote the establishment and maintenance 
of high ethical standards and high standards of professional practice among 
persons working in human genetics.96
The HGSA policies deal with predictive testing, and emphasise that the benefit of 
testing for the child should be the paramount consideration. 




The policy, Predictive	Testing	 in	Children	and	Adolescents	2005,	takes the following 
recommendations from the policy Presymptomatic	and	Predictive	Testing	for	Genetic	
Disorders 2005:
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•	 Children should only have pre-symptomatic and predictive testing when the 
resulting information will be used to help with their health management in the 
immediate future;
•	 The age at which testing can be offered to a child should be given flexible 
consideration by the testing team;
•	 Where the risk status for a disorder has been established for a child, either 
prenatally or after birth, the child should be informed that the information 
will be available once she or he has reached a level of maturity consistent with 
understanding its implications;
•	 An asymptomatic at-risk child’s DNA should not be collected and stored for 
research or for possible future use by the child or the family;
•	 Pre-symptomatic and predictive DNA testing should not be used to determine a 
child’s suitability for adoption.98
The Presymptomatic	and	Predictive	Testing	for	Genetic	Disorders policy states that the 
practice guidelines are intended to guide all health professionals who undertake such 
testing. Professionals are advised to be aware of other sources of information and 
guidelines, and to note that there may be relevant Commonwealth and State laws that 
would take priority over the guidelines.99
The HGSA policy indicates that genetic health professionals both within Australia 
and internationally follow international guidelines that recommend testing of 
children under the age of eighteen should only be considered when the result is likely 
to be of direct	benefit to the child through medical surveillance, use of prevention 
strategies or other medical interventions. The policy acknowledges that adherence 
to such guidelines has been challenged by some parents and writers on the basis that 
there may be other benefits, which do not come under the general category of medical 
benefits, for children and their families. Such benefits might include preparing a child 
for future health issues, empowering parents, avoiding professional paternalism and 
avoiding uncertainty for parents and children. 




The policy categorises the underlying ethical principles regarding predictive testing 
in children as being autonomy, non-maleficence and beneficence, and notes that 
the practical application of the principles may vary depending on the nature of the 








The policy then appears to utilise a consequentialist framework of benefits and 
harms.
3.3.2  Non-maleficence
The HGSA policy sets out potential harms that might arise from predictive testing 
of children:
•	 Disclosure of test results to others, resulting in loss of privacy;
•	 Discrimination and loss of options directly arising from test results;
•	 Stigmatisation in the family and community, with reduced opportunities for 
education, marriage and reproduction;
•	 Alteration of parenting as the result of knowing the child’s genetic status.
The policy omits to mention the possible psychological harms, such as sadness, 
fear, anger, despair or even depression, that might be visited on a child as a result of 
genetic testing, particularly on a child who tests positive for an untreatable condition. 
(However, in the section ‘Beneficence’, the policy suggests that benefits and harms 
can be categorised into medical, psychological and reproductive issues.) 
3.3.3  Beneficence
The policy refers to the need to consider the interests of the child, parents and 
family; benefits and harms should be categorised into medical, psychological and 
reproductive issues. The policy stipulates that the best interests of the child must 
prevail and that the health professional must be an advocate for the child during pre-
test counselling of the family and the child.
3.3.4  Family discussion
Parents should be encouraged to make their children aware, at an appropriate age, of 
a genetic condition in the family, and the implications, and to rear the child with this 
knowledge. Being able to discuss this information with the family over a number of 
years at different stages of maturity will ultimately enable the child to make a better 
informed choice about predictive genetic testing as an adult. 
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3.3.5  Genetic counselling
As a corollary, genetic counselling is also essential as a prelude to predictive genetic 
testing. Counselling should be provided in language and terminology that can be 
readily understood by the child and parents. Parents should be encouraged to view 
predictive test results in terms of benefits to the individual child, rather than benefits 
to another person or group. When parents and child conflict, the counsellor should 
act as an advocate for the child, whilst recognising that the child is part of the family. 
Counselling needs to focus on the family and child both together and separately. In 
some cases referral to further counselling from appropriate health professionals will 
be appropriate.
3.3.6  Decision-making
Predictive genetic testing of children should not be performed without a child’s 
knowledge and participation in the genetic counselling process. However, in some 
circumstances, as when predictive testing is medically indicated in young children, 
parents will need to make decisions alone. The Guidelines give the example of testing 
babies for a mutation in the RB1 gene. Mutations in the RB1 gene usually result in 
retinoblastoma – early-onset malignant eye tumour(s), which may lead to blindness 
or even death among affected children, if untreated.
Parents need to be advised before testing that genetic testing of a child can identify 
other family members at risk and non-paternity or adoption, and be encouraged 
to consider the implications and decide how such information would be handled 
should it arise.
3.3.7  Parent-child conflict
• Predictive testing of a child should only be used where the result is of direct 
benefit to the child, and not to resolve conflict within a family or between family 
members or other concerned parties e.g. in relation to reproductive, custody, 
social welfare or future education issues;
• During counselling it must be recognised that a child may not be able to exercise 
free choice in the face of strong parental options or parental discord.
It is interesting to note that where a person is unable to consent to predictive genetic 
testing because of mental or physical illness or disability, then the more general 
HGSA policy, Presymptomatic	and	Predictive	Testing	for	Genetic	Disorders,	states that 
a genetic sample should only be taken ‘if it is essential to reach a diagnosis which will 
be of value to the individual or other family members’102 (emphasis added) and once 




There would thus appear to be a lower threshold for conducting predictive testing 
on ill or disabled people than for predictive testing of children. The HGSA policy, 
Predictive	Testing	in	Children	and	Adolescents,	places the child’s interests at the apex 
of considerations – the benefit for the child of testing should be the paramount 
consideration. Whereas, from the more generalised policy, it appears that ill or 
disabled people can be used as a means to an end. 
3.3.8  Discrimination
• Children should be protected from discrimination on the basis of predictive 
testing results, including in insurance and employment matters;
• Where potential for discrimination exists, the children, parents and 
professionals involved should be advised;
• Predictive testing results should only be made available to the child and to those 
for whom appropriate permission has been granted;
• Predictive testing should not be used to determine a child’s suitability for 
adoption or foster care; and
• Predictive testing should not be used to alter a child’s social circumstances. 
.  clinical genetics society (uk), 
The	Genetic	Testing	of	Children,	Report of a Working Party of the United Kingdom 
Clinical Genetics Society (CGS), chaired by Dr Angus Clarke, aimed to:104
• Examine current attitudes and practices in relation to genetic testing of children;105
• Focus attention on any difficulties raised by such testing; and
• Make appropriate recommendations about future practice.106
The Report briefly outlined the ethical concerns raised by the genetic testing of 
children. The Working Party observed that an early consensus was reached, by those 
working in the field of predictive testing for HD, that children should not be tested.107 
HD test results could be burdensome, even when they supposedly bore ‘good news’, 
and a sizeable majority of ‘at risk’ adults (85 to 90 per cent) did not undergo predictive 
testing for HD.108
The	right	of	the	child	to	decide	in	adult	 life	whether	or	not	to	be	tested	would	
be	 removed	 if	 their	genetic	 status	was	determined	at	 the	 request	of	parents	or	
others.109	
The Working Party concluded that similar ethical concerns arose in respect of 
other adult-onset neurodegenerative disorders, e.g. Alzheimer’s disease and prion 
dementia.110 
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The Report highlighted documented evidence of discrimination on the basis of 
genetic status in insurance and employment, raising the concern that predictive 
genetic testing may have flow-on negative effects for children.111 
The Report referred to two potentially problematic ethical areas in relation to genetic 
testing of children in particular: predictive genetic testing for late-onset (usually of 
autosomal dominant inheritance) conditions in which clinical manifestation was 
unlikely until well into adult life (and for which early treatment or surveillance for 
complications would not help); and testing for carrier status where there were no 
implications for the child’s own health, but the existence of the condition could affect 
offspring.112
The future autonomy of children to decide for themselves whether or not to be tested 
could be undermined in both of these areas. Similarly the confidentiality to which an 
adult would be entitled would also have been breached when results were disclosed 
to parents.113
Noting that many did not apply to genetic testing for early-onset conditions or 
conditions for which there were timely medical interventions, the Working Party 
listed potential harms of genetic testing of children as including:
• Damage to self-esteem;
• Distortion of the family’s perception of the child;
• Loss of future autonomy and confidentiality;
• Discrimination in education, employment and insurance;




The potential advantages listed were:
• Opportunity for the child to adjust to his or her circumstances;
• Fostering of openness within the family;
• Resolution of parental uncertainty;
• And, for carrier status test, ensuring testing has been offered to the whole family.
3.4.1  Legal considerations
The Working Party observed that there had been significant recent developments in 
child law. Most notable were the case of Gillick115 and the Children Act 1989, both of 
which had considerably altered the legal status of children. There was a new prevailing 
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view that parents had responsibilities for the care of their children rather than rights 
over them, as such, and that they were expected to exercise their responsibilities in 
the best interests of their children. Consequently, parental decisions were to be made 
according to the welfare of the children and not to alleviate parental anxiety. Courts 
could be called upon to settle any disputes, but occasions in which this would be 
necessary would be rare.116
The	 courts	 have	 suggested	 that	 children	 should	 be	 given	 the	 chance	 to	 take	
decisions	on	medical	care	for	themselves	if	it	is	possible	to	wait	until	they	are	able	
to	do	so	without	risking	their	health.117	
The Report contended that the law ensures that decisions about medical testing are 
made jointly by parents and professionals;118 although parents, in effect, have a veto 
because testing cannot be carried out without their consent.119 
Parental consent must be obtained when children do not have the intellectual capacity 
to agree to treatment, and such consent may be given until the child reaches eighteen.120 
The Report further states that the consent of one person with parental authority may 
suffice unless there is a Court order dealing specifically with the matter. 
The Report charges that, although children cannot be tested without their own or 
parental consent, health professionals can equally not be compelled to offer care that 
they consider inappropriate.121 When testing is contrary to a child’s interests, health 
professionals may justifiably refuse to test, even if a parent requests it.122 
Nor are health professionals obliged to disclose information on the genetic status 
of a child when they believe it would harm the well-being of the child. In principle 
parents are entitled to see their children’s medical records,123 but health professionals 
can refuse to reveal information when they believe that to reveal it would cause 
serious harm to the physical or mental health of the child or others.124
General principles of malpractice law also necessitate that health professionals 
give serious consideration to the welfare of child patients. The Report declares 
that professionals are negligent if they fail to practise in a manner accepted by a 
responsible body of professional opinion in their specialty.125 
Given	the	general	consensus	that	it	is	unwise	to	test	children	for	HD,	to	do	so	might	
well	be	regarded	as	negligent	except	 in	very	particular	circumstances.	 In	other	
areas,	however,	both	 testing	and	refusing	 to	 test	would	probably	be	acceptable	






The CGS noted that most disputes among family members and/or health 
professionals could be resolved by sensitive counselling, and recourse to the law was 
uncommon.127 
The Report lamented the lack of evidence upon which to base policies. People’s 
attitudes (including those on the Working Party) were likely to be influenced by 




The concerns were that parental attitudes towards a child might change and that poor 
expectations about the child’s future mental, physical and emotional development 
could be self-fulfilling. This could result in a loss of self-esteem for the child. However, 
there was little evidence that testing would produce such harm. The Working Party 
speculated that this may have been because testing did not actually cause such 
damage, or because it had been of such limited scope in the past that the resulting 
harm had not come to light because evidence of it had not been sought’.129
The Working Party remarked that it had had to arrive at the answers ‘in the absence 
of adequate empirical data, relying upon our various experiences and upon our 
concern to maintain the generally accepted principles of medical ethics’.130
3.4.2  Predictive testing (when no direct health benefit to child)
The Working Party’s consensus view was that there should be a general presumption 
against predictive testing, although circumstances might arise where it was 
appropriate. 131 
The Report reasoned that there was a precedent, in terms of HD testing and children, 
whereby the general prohibition was based upon the likely effects of such testing 
rather than empirical evidence of harm. Only 10 to 15 per cent of ‘at risk’ adults 
chose HD testing,132 and those people underwent extensive genetic counselling in 
which they were required to address the effects the test results were likely to have on 
their entire lives (e.g. insurance, home ownership, career, marriage, reproduction). 
It could be hard for parents to understand the disinclination for testing, felt by many 
‘at risk’ adults, which their child too might come to experience. Sensitive genetic 
counselling exploring the issues would hopefully help parents to appreciate the 
limitations of their own perspectives and the fact that their feelings might well differ 
from the child’s views in the future.133 
The report reiterated that there was little evidence as to any negative effects from 













The limited empirical evidence and the ethical consequences of childhood testing 
(loss of adult autonomy and confidentiality and the possibility of causing harm to 
the developing child) led the Working Party to advocate a cautious policy, tending 
towards the non-maleficence or ‘first do no harm’ principle.135 
The Working Party argued that were also sound legal reasons for health professionals 
to make decisions about genetic testing based on the long-term best interests of the 
child. Not doing so could result in action against them for acting, even at the behest 
of the parents, against the child’s interests.136
However, the Report also duly noted that experience and information would increase 
in the future and, additionally, the apparent disadvantages of predictive testing for 
HD might not apply to all disorders or every case of HD.137 
The Report charged that testing should clearly be available where there were health 
benefits to be gained, but that it was generally inappropriate to undertake predictive 
testing purely to satisfy professional curiosity (except in certain types of research) 
or to relieve parental anxiety. There may be circumstances in which such testing 
is justified but ‘the possible emotional harm to the child, the abrogation of their 
autonomy and the breaching of their confidentiality, will generally outweigh the 
possible benefits’ that the Working Party could see.138 The Report also noted that 
similar concerns could arise in terms of susceptibility testing for common multi-
factorial disorders. 139
3.4.3  Carrier testing
The Working Party maintained that the arguments in relation to carrier testing were 
less clear and there was no consensus amongst health professionals. The Working 
Party considered that carrier testing in children should generally be deferred. The 
arguments for and against could be and often were discussed in genetic counselling. 
Parents often saw that carrier testing could be delayed without disadvantage, and that 
the child could eventually participate in the decision as an autonomous person. 140 
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The Report addressed a number of arguments in favour of carrier testing in 
children:
•	 It may better for a child to know about their carrier status in childhood: 
this may then be accepted as a simple matter of fact, without the emotional 
problems that could arise from a later disclosure.
The Report opined that this argument was only valid if the only alternative to not 
testing was complete silence on the issue. The Working Party did not support the 
idea that a decision not to test entailed not discussing carrier status risks with a 
child. Indeed, they surmised that discussion of carrier status might be easier without 
conclusive knowledge. It would not be difficult to explain to a child that the decision 
regarding testing was for them to decide when they were older. Such granting of 
control and autonomy could enhance their self-esteem, and allow them to come to 
terms with the possibility that they may be confirmed as a carrier when older.141 
Whilst 50 per cent of children ‘at risk’ for carrier status may have their lives simplified 
by testing, the possible benefits for those children needed to be weighed against 
the possible harm to the children identified as carriers. Such knowledge could be 
particularly harmful in families where some children were confirmed as carriers 
and others were absolved from risk. (The Working Party observed that being a non-
carrier could even be disadvantageous in some families.)142
•	 Testing their child may decrease the level of anxiety of the parents simply by 
giving them this knowledge.
The Report commented that anxiety could increase if a child tested positive as a 
carrier, and that testing might need to be repeated in the future as techniques 
improved.143 
•	 There is no direct evidence to indicate that carrier testing in childhood is 
harmful.
The Working Party responded that there was also no good evidence of any benefits. 
Some evidence indicated that carrier status knowledge could have adverse effects 
that may be magnified if identified involuntarily when young and if the child were 
labelled a carrier by the whole family.144 The Working Party claimed that it arrived 
at its conclusion based on the evidence currently available and the recognition that 
further research was needed.145 
The Report also referred to problems relating to stigmatisation; fear of stigmatisation; 
and increased health concerns and distress amongst carriers.146 
•	 Carrier testing in childhood avoids urgent carrier testing in young teenage 
pregnancies (often concealed until late pregnancy).
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The Working Party contested that this argument relied upon presuppositions: that 
teenagers would want carrier testing, and that they would want prenatal testing. 
The report outlined practical alternatives to urgent carrier testing: the doctor could 
inform the teenager about the risks and refer her for genetic counselling (and 
possible testing) if desired; and adolescents should be given proper information 
about reproduction and contraception.147 
•	 Testing in childhood ensures that testing is at least performed, and may absolve 
the doctor of his responsibility in this regard.
The Working Party commented that giving information to the family about carrier 
status did not guarantee that the child would receive appropriate information at an 
appropriate age. (Indeed, anecdotal evidence suggested that parents found it no easier 
to give children information about genetic disease than to give them information 
about sex and reproduction.) Even when a child was tested, the CGS believed that 
health professionals retained a responsibility to ensure that the future adult was 
offered genetic counselling at an appropriate age. This would ensure that the adult 
had the opportunity to discuss relevant issues, and that any advances in medical 







The Working Party suggested several possible ways of ensuring that a child was 
offered carrier testing at an appropriate age:
1. Clear transfer of responsibility from the doctor to the family, so that the onus of 
offering genetic counselling and testing lies with them.
2. Clear transfer of responsibility to the family’s GP who can prompt a genetic 
referral when the child is old enough to be directly involved.
3. Continued involvement with the family through an active genetic register, with 
regular long-term follow-up to keep in touch with family members, even when 
they move. 
The Working Party was most in favour of the third option, despite the expense.150 
The Report summarised the discussion as tending towards the view that carrier 
testing in childhood might not be appropriate, particularly where there were 
practical alternatives. Unintentional carrier testing should be avoided where possible, 
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and further research was needed to establish the psychosocial consequences, adverse 
effects and benefits of carrier testing in children.151
3.4.4  Who has the right or responsibility to arrange for the genetic testing of children?
Parents
There was no clear consensus as to this issue amongst British health professionals. 
Decisions were to be made according to the best interests of the child; however, no 
blanket policy would be defensible.152
Given	that	the	genetic	test	results	will	have	no	medical	management	implications	






The Working Party declared that where testing was possibly medically advantageous 
to a child, then medical practitioners clearly had an obligation to ensure that it was 
carried out. Where testing might be of interest to the future adult for health reasons 
or to enable informed reproductive decisions, the offer of genetic counselling and 
possibly genetic testing should be made when the person was mature or in early adult 
life (which might require establishment of an active genetic register).154
Medical practitioners need not assume a duty to instigate carrier or predictive testing 
and, when such testing was requested by others, they had a right to refuse if they 






















































.  genetic interest group, 
3.5.1  Response to the CGS report158
The Genetic Interest Group (GIG), a national umbrella organisation of more than 
one hundred charities, voluntary organisations and support groups, responded 
to the 1995 CGS report The	 Genetic	Testing	 of	 Children. It opined that the age at 
which a young person became sexually active might be a better indicator of when to 
consider genetic testing than any fixed age, given that it was ‘the age at which genetic 




GIG considered the United Kingdom CGS report to be ‘deficient and flawed’ in many 
areas, and stated that it had a different perspective, informed by the experiences of 
families directly affected by genetic disorders.160 
GIG contended that the CGS report was overly concerned with the potential 
psychological harms caused by genetic testing: ‘With little evidence, this seems 
to reflect more the fears of doctors that they will be held responsible for negative 
reactions, rather than the needs of families’.161
In their experience children could cope with information about themselves from an 
early age and it was more frequently adults who had problems in giving information. 
Their main focus was to argue for the right of parents to have their children undergo 
genetic testing, except for late-onset conditions.162
3.5.2  Pre-symptomatic diagnosis of childhood-onset conditions
GIG argued that there were many reasons to allow this type of testing, despite a lack 
of pre-symptomatic medical interventions, including ‘possible freedom from anxiety; 
facilitating open relationships; and the parents’ need to secure the best environment 
they can for themselves, the child who will develop the disorder, and other children 
in the family. “Best environment” might mean a house with suitable access, located 
near a school and hospital. It might also mean securing particular kinds of work. It is 
a major defect of the report that it makes little mention of the non-medical reasons 
for testing’.163 
GIG accused the CGS report of being vague as to whether pre-symptomatic 
diagnosis of childhood onset conditions should be performed,164 and recommended 
that ‘Subject to the limitations of existing law, parents have the right to make an 






3.5.3  Testing for carrier status
GIG argued that the same arguments in favour of allowing parents to consent to pre-
symptomatic testing of their child for childhood-onset conditions also ‘hold good’ in 
respect of carrier testing. GIG considered that in many or even most cases the issue of 
carrier status would be best dealt with at puberty or when the child became sexually 
active. However, earlier knowledge of carrier status might help a child to adjust better 
to the information, rather than being confronted with the information at puberty 
when already going through a process of adjustment. Additionally, younger children 
might well already be wondering whether they would be affected in some way by a 
heritable mutation seen in their family.167
GIG argued that the seriousness of carrier information had been exaggerated because 
it was new, and that suggestions that children might be treated differently if known to 
be carriers, or that they might be given erroneous information, were unsubstantiated: 
‘the vast majority of people are better able to understand the implications than they 
are often given credit for’.168
While the response recommended that children should only be tested when they 
were of an age to be involved in the decision, the emphasis appears to remain on 
parents giving informed consent to testing of their child, rather than the minor 
giving informed consent:
After	 suitable	 counselling,	 parents	 have	 the	 right	 to	 make	 an	 informed	 choice	
about	 whether	 or	 not	 to	 have	 their	 children	 tested	 for	 carrier	 status.	 Ideally,	
children	should	only	be	tested	when	of	an	age	to	be	involved	in	the	decision.169	
GIG argued that the child could still choose whether or not to use the information 
when making reproductive decisions as an adult.170
3.5.4  Predictive testing for adult-onset conditions
GIG agreed with the United Kingdom CGS that ‘Children should not be tested 





.  canadian Paediatric society, 200
The Canadian Paediatric Society (CPS) Guidelines	 for	 Genetic	 Testing	 of	 Healthy	
Children (Position Statement (B2003–01))173 deals with the testing of healthy children, 
in particular when there is no foreseeable timely medical benefit.174 The guidelines do 
not go into issues relating to diagnosis of symptomatic children; genetic testing for 
the purpose of enhancing monitoring, prophylaxis or treatment in a healthy child at 
risk for a genetic condition; or newborn screening.175 
The position statement surmised that it was difficult to predict whether childhood 
testing would be beneficial to that individual in adulthood. Surveys revealed that 
genetic testing of minors for late-onset disorders occurred with relative frequency,176 
despite research indicating that the willingness of asymptomatic adults to have 
genetic testing for late-onset conditions or carrier status was highly variable across 
individuals (although there was higher preference to be tested where prophylactic 
measures might be taken in relation to a disorder tested for).177 
3.6.1  Social concerns
The statement contends that there is significant societal concern that stigmatisation 






3.6.2  Psychological concerns
Studies of people at risk for HD demonstrated that a positive result in a well-prepared 
person might not be as devastating as might be expected. However, knowledge that 
one is not at risk had been shown to increase psychological stress in some cases. 
The statement also referred to advantages in not knowing one’s carrier status: relational 
bonds could be shattered when true ‘at-risk’ status is shown. More generally, family 
dynamics could be affected by testing. Testing might confer a psychological impact 
on not only the child being tested but also the parents, who might feel responsible 
for a positive test result.180
Testing for carrier status was often perceived as less psychologically risky than testing 
for late-onset disorders, because generally carriers were and would remain unaffected. 
However, that was not to say that carrier testing was entirely without impact, surveys 
demonstrating that the impacts can variously include negative effects,181 positive 
attitudes182 and misunderstandings.183 
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3.6.3  Consent issues
The position statement contended that whilst ‘the highly sensitive nature of genetic 
testing and historical concerns of societal oppression’184 had meant that rights to 
autonomy and self-determination had underlined an emphasis on informed consent, 
autonomy was not an independent concept but was relationally based.
Individuals made heath-care decisions based on responsibilities to others,185 and 
generally ‘the interests of the family and the child are intricately related and difficult 
to separate’.186
The statement emphasised the paramountcy of the best interests of the child and the 





The statement stipulated that consent must be informed, voluntary and given by a 
competent individual.188 
3.6.4  Reproductive privacy concerns
Whilst carrier testing may be considered less psychologically risky because the carrier 





If an infant or child is tested for carrier status then the parents and anyone else they 
divulge the information to will know of their status, infringing their right to autonomy 
in the information. And, as with testing for late-onset conditions, the variability in 
adult uptake of carrier testing made it difficult to predict whether carrier testing for 
a child would be in his or her best interests.190 
3.6.5  Parental requests for genetic testing
Parents and health-care providers who request genetic testing must have a good 





Having weighed up the benefits versus the potential harms, a health-care provider 
should not feel obligated to take part in the testing, where she or he sees scope for 
undue harm. 
Although	 parents	 are	 the	 decision	 makers	 for	 their	 children’s	 therapeutic	
treatment,	 they	 do	 not	 have	 authority	 over	 non-therapeutic	 interventions,	
including	genetic	testing.192
On those exceptional occasions where it appears that not testing would be of greater 
harm than testing, such cases should be decided with the succor of ethics and legal 
expertise.193
3.6.6  Recommendations of the CPS
•	 In all situations where genetic testing of healthy children is considered, parents 
should be informed of potential psychological and social risks associated with 
testing. Open discussion regarding familial genetic risk, in an age-appropriate 
manner, should be encouraged within the context of the family unit. The best 
interests of the child should be the primary consideration when contemplating 
testing. Appropriate counselling and genetic service involvement should be 
instituted. 
•	 Timely medical benefit to the child should guide genetic testing. That is, genetic 
testing to confirm a diagnosis in a symptomatic child, to allow for adequate 
medical monitoring, prophylaxis or treatment in a child at risk for a genetic 
condition that will occur in childhood is appropriate. 
•	 For genetic conditions that will not present until adulthood (susceptibility or 
predictive testing), testing should be deferred until the child is competent to 
decide whether they want the information.
•	 For carrier status for conditions that will be important only in reproductive 
decision making, testing of children should be discouraged until the child is able 
to participate fully in the decision to be tested. …
•	 In exceptional circumstances where parents insist that genetic testing of healthy 
children be carried out where there or no medical or other benefit to the 
child, the physician is not obligated to carry out testing that is not in the best 
interests of the child. In exceptional circumstances, not testing may create more 
harm than testing. In these cases, a referral for ethics or legal opinion may be 
appropriate. ...194 
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.7  Provincial advisory committee on new Predictive genetic technologies, 200 
In its report of 30 November 2001, Genetic	Services	in	Ontario	–	Mapping	the	Future,195	
the Provincial Advisory Committee on New Predictive Genetic Technologies196 stated 
that genetic testing of children in the absence of timely medical or psychosocial 
benefits, or when the benefits would not accrue until adulthood, could cause 
serious psychological harm, expose children to stigmatisation and discrimination 





.  canadian college of medical geneticists, 2000
The Canadian College of Medical Geneticists (CCMG) position statement,	Genetic	
Testing	 of	 Children, supports the principles outlined in the American Society of 




In	 cases	 where	 the	 genetic	 testing	 of	 children	 involves	 detecting	 possible	 risks	
to	their	offspring,	rather	than	risks	to	themselves,	a	decision	as	to	whether	the	
potential	harm	of	 such	testing	outweighs	 the	benefit	 is	often	complex,	and	the	
answer	may	not	be	clear.	…	The	age	at	which	a	child	may	be	offered	the	test	can	
be	the	age	of	responsible	understanding,	rather	than	the	age	of	majority.199
.  american society of human genetics/american college of medical  
 genetics, 
The American Society of Human Genetics/American College of Medical Genetics 
(ASHG/ACMG) Report (1995), Points	 to	Consider:	Ethical,	Legal,	 and	Psychosocial	
Implications	of	Genetic	Testing	in	Children	and	Adolescents,200	states that:
Although	 parents	 are	 presumed	 to	 promote	 the	 well-being	 of	 their	 children,	 a	
request	 for	a	genetic	 test	may	have	negative	 implications	 for	children,	and	the	
health-care	provider	must	be	prepared	 to	acknowledge	and	discuss	 such	 issues	
with	families.201
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The Report focuses on genetic testing in response to a family history of disease, or 
parental requests, and not genetic screening (population based, e.g. newborn or 
school screening programmes). 
The Report is ‘grounded in’ the following social concepts:
1. The primary goal of genetic testing should be to promote the child’s well-being.
2. The recognition that children are part of a network of family relationships 
supports a non-adversarial approach to potential conflicts, and emphasises a 
deliberative process that seeks to promote the child’s well-being within this 
context.
3. Parents and professionals should be attentive to the growing and developing 
child’s increasing interest and ability to participate in decisions about his or her 
own welfare.202
The report recommends that counselling and communication with the child 
and family include an assessment of the potential harms and benefits of testing; 
determination of the child’s decision-making capacity; and advocacy on behalf of 
the interests of the child.203 
3.9.1  Benefits and harms of genetic testing in children
The Report states that parental requests for genetic testing on non-medical grounds 
(e.g. for psychosocial reasons) are the most controversial aspect of the discourse on 
genetic testing of children. Some geneticists approved of such testing, whilst others 
did not approve where there was no immediate medical benefit to the child. There 
were already some protocols in place regarding the testing of children under eighteen 
for HD and BRCA mutations.204 
As with other medical treatment, the welfare of the child is the guide to action 
or inaction in terms of genetic tests when the child does not have the capacity to 
give voluntary informed consent. Thus, decisions should be based on assessment 
of the possible benefits and harms, which may emerge from medical, psychosocial 
and reproductive issues, and may also have implications for the child, his or her 
immediate family, and more distant relatives.205
3.9.2  Medical issues
Treatment	and	prevention – Genetic tests with the potential for therapeutic benefits for 
children are those most likely to be supported by the public and health professionals, 
and of course the children themselves and their families.206 
While medical benefits can sometimes be gained from childhood diagnosis, other 
outcomes are more contestable, and some even harmful. For example, a childhood 
diagnosis can result in increased tests, monitoring and treatment regimens (at a 
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cost) with no proven benefits (as the Report contended could be the case with pre-
symptomatic diagnosis of cystic fibrosis).207 
Thus,	 the	 potential	 for	 benefit	 of	 unestablished	 treatment	 and/or	 prevention	
regimes	 is	a	questionable	 justification	 for	 testing.	Empirical	 verification	of	 the	
benefits	and	harms	of	prevention	and	treatment	should	precede	recommendations	
for	routine	testing	(Wilfond	and	Nolan	1993;	Marteau	1994).208
Surveillance – For susceptibility mutations, monitoring is sometimes associated with 
effective treatment (as in the case of retinoblastoma).209 However, medical benefits 
accruing from surveillance are less certain in other cases. The benefits of genetic tests 
diminish when early detection has no effect on prognosis.210 
Reduction	of	surveillance – If a child is excluded from risk by genetic test results then 
he or she could benefit from a reduction or cessation of surveillance.211
Refinement	of	prognosis – Genetic testing can help refine prognosis when it leads to a 
precise diagnosis or when a genotype is well correlated with a phenotype. 212 
Clarification	 of	 diagnosis – Genetic testing can help clarify an uncertain diagnosis 
if information from other sources is inconclusive. Testing children can also benefit 
other family members, when it is necessary to improve the reliability of linkage and 
mutation analyses.213
3.9.3  Psychosocial issues
The report asserts that psychosocial issues could be exacerbated or alleviated by 
genetic test results, and that:
The	presence	of	severe	anxiety	of	other	psychopathology	should	be	an	indication	
for	 further	 psychological	 intervention	 –	 and	 not	 necessarily	 an	 indication	 for	
genetic	testing.214	
Reduction	of	uncertainty – The Report highlights research on HD demonstrating a 
reduction in anxiety both in persons determined not to be at risk, and in those found 
to be at increased risk. The least reduction in uncertainty was amongst those who 
had indeterminate test results.215 Even where the reduction in uncertainty leads to 
knowledge that one has a life-shortening disorder, testing can lead to appropriate 
adjustment and preparation.216 
Both parents and children can benefit from the reduction in uncertainty that testing 
brings: a mutation-positive result allows a family to confront the condition and 
issues head-on, whilst a mutation-negative result can lead to significant psychological 
benefits for both child and family.217 
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Alteration	of	 self-image – The Report lists a number of potentially negative effects 
genetic testing may have on a child’s self-image: children who test positive for 
a disorder may lose self-esteem at a point in their lives critical to self-identity 
development;218 children’s understanding of disease and illness is often limited, and 
may result in self-blame if affected;219 potential loss of privacy in the information 
could exacerbate self-esteem problems; unaffected children may carry ‘survivor-
guilt’, in the knowledge that one or more siblings may develop and possibly die from 
a serious genetic disorder.220 
On the flipside, some affected children may come to ‘own’ their condition, and view 
it as normal, and develop positive attitudes of identification with similarly affected 
family members.221
For children at risk of being carriers, not testing could have unexpected benefits: 
not knowing the status could allow a child to assume carrier status and thus share 
any familial burden of the illness;222 the assumption of carrier status can provide an 
important source of self-identity (which could be altered if the child is found not to 
be a carrier). 
Impact	on	family	relationships – The Report suggests that affected children may be 
overindulged, rejected or treated as a scapegoat,223 or be victims of the ‘vulnerable 
child syndrome’ and overprotected and restricted from normal childhood activities.224 
Meanwhile, unaffected siblings may feel disenfranchised by the attention and concern 
shown to an affected sibling.225
Genetic testing of children can also unintentionally provide predictive genetic 
information about other family members. This may be perceived as a benefit or 
harm. 
Impact	on	 life	planning – The Report asserts that the possibility of serious disease 
or early death can affect educational goals; occupational choices; specific career 
plans; home ownership;226 retirement planning; obtaining life, disability or health 
insurance;227 possible adoption (for parents and child);228 and choice of domicile – 
families may wish to live closer to family, other support systems or adequate medical 
facilities.229
Genetic status can also lead to stigmatisation and inappropriate discrimination in 
a variety of areas,230 such as education, relationships, employment and insurance.231 
Affected people may not be encouraged to reach their full potential and may have 
difficulty accessing education or employment if premature death or frailty is 
foreseen.232
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3.9.4  Reproductive issues
The Report deems any reproductive benefits gained from genetic testing, such 
as knowledge of carrier status, to be of little value to children. The imparting of 
carrier-status results may be done in such a way and at such a time or age as to be 
incomprehensible and essentially useless for children. 
However, from a parental perspective, knowledge of a pre-symptomatic condition in 
a child could affect their reproductive choices, in terms of utilising prenatal testing, 
or timing or spacing of children.
3.9.5  Promoting interests of children and families 
Parents	generally	have	the	authority	to	make	medical	decisions	for	their	children.	
This	 authority	 may	 be	 limited	 if	 a	 decision	 is	 likely	 to	 cause	 a	 child	 serious	
harm	without	 the	prospect	of	 compensating	benefit.	What	 further	 complicates	
these	issues	in	genetic	testing	is	the	uncertainty	about	the	putative	benefits	and	
harms.233	
The Report notes that as children grow and mature, their ability to participate in 
decisions increases, and there may be occasions where their choices clash with the 
wishes of their parents. These issues highlight the need for the provider to explore 
both the interests of the children and the interests of their parents.234 
3.9.6  Presumption of parental authority
The Report declares the presumption of parental authority a fundamental principle 
for families and professionals in discussions and decisions regarding the genetic 
testing of children.235
Limits	of	parental	authority – However, the Report asserts various limits to parental 
authority. Where there are objective reasons to believe that a decision or action has 
significant potential for an adverse impact on the health or well-being of a child, 
parental authority is limited, as in child abuse situations.236 Additionally, parents are 
required to provide certain medical benefits for children in some cases, even when 
contrary to their own beliefs – e.g. newborn screening for PKU, some immunisation 
programmes and life-saving blood transfusions. Conversely, parents may also be 
restricted in choosing certain medical interventions for their children, including 
involuntary sterilisation, or participation in harmful research trials.237
In the clinical setting providers can refuse to participate in diagnostic or therapeutic 
interventions that have no or few benefits and more than minimal risks or cost 
(patients are not free to assert entitlements to services from third parties).238 Where 
this is the case the Report recommends providers issue an explanation for their 
refusal and offer a referral. 
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3.9.7  The decision-making capacity of the child
Children’s cognitive skills and moral reasoning abilities mature over time and at 
varying rates.239 As they develop they become capable of greater participation in 
decision-making; and, indeed, participation in important decisions can further 
enhance development of such skills. 
The Report states that children can begin to participate in decisions by the age of 
seven because they have sufficient cognitive and language skills to understand 
some information. Therefore, in the United States seven-year-olds are entitled to 
give ‘assent’ to participation in research.240 The ability to ‘consent’ relies upon the 
competence to make an independent choice whereas the ability to ‘assent’ merely 
requires a rudimentary understanding of risks and benefits and a decision to 
participate or not.241 
The Report charges that by the age of twelve or fourteen some children will have 
sufficient decision-making capacity to evaluate specific risks and benefits of tests and 
treatments.242 
3.9.8  The provider as fiduciary for the child
The supposition of the role of fiduciary requires that providers be conscientious 
about considering requests for testing, as well as requests for non-disclosure.
Assessing	 requests	 for	 testing – Whilst providers are generally meant to give non-
directive advice, they may discourage actions potentially adverse to the well-being 
of any child concerned. Providers must ultimately balance the responsibility to the 
health and well-being of the child with the responsibility to adhere to the parents’ 
wishes. This should be evaluated by assessing the relative benefits and harms of each 
course of action; an assessment is rendered more difficult in situations where the 
factors are largely psychosocial rather than medical.243
The Report urges that, until more evidence is available about the harms and benefits 
of genetic testing, providers must adhere to the principle ‘first do no harm’. Where 
there is uncertainty it may be more prudent to avoid the possibility of harm rather 
than provide unclear benefits. There could be a rebuttable presumption: defer testing 
until the risk–benefit ratio is favourable.244
Parents may overestimate the powers or benefits of genetic testing or be unaware of 
risks. Sometimes the provider may need to weigh the benefits to the family versus the 
benefits to the child, as when parents request predictive testing for family planning 
or socioeconomic reasons (e.g. how much to save for college).245 
The Report propounds the utility of consulting with other providers (including ethics 
committees) in order to evaluate harms and benefits, decision-making capacity and 
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voluntariness. If consensus is unattainable then a provider may refuse to participate 
and may refer a family to providers who might be more willing.246
Assessing	 requests	 for	 non-disclosure – The Report highlights the potential conflict 
between the parents’ interests in making decisions for the well-being of their child 
and the child’s interests in self-determination. Justifying requests for non-disclosure 
becomes increasingly difficult as a child matures, even in situations where disclosure 
would not promote his or her own well-being.247 Factors to be considered include 
age, the need for medical interventions and the need for the child’s participation in 
therapeutic interventions. The Report recommended that people should be informed, 
upon reaching adulthood, of the existence of such tests, and be given the option of 
knowing the results.248
The Report lists ‘Points to Consider’ when genetic testing of children or adolescents 
is proposed. 
3.9.9   The Impact of potential benefit and harms on decisions about testing
1. ‘Timely medical benefit to the child should be the primary justification in 
genetic testing of children and adolescents. Under this condition genetic testing 
is similar to other medical diagnostic evaluations. Medical benefits include 
preventative measures and therapies, as well as diagnostic information about 
symptomatic children. If the medical benefits are uncertain, or will be deferred 
until a later time, this justification for testing is less compelling.’
2. ‘Substantial psychosocial benefits to the competent adolescent also may be a 
justification for genetic testing. …’
3. ‘If the medical or psychosocial benefits of a genetic test will not accrue until 
adulthood, as in the case of carrier status or adult-onset disease, genetic testing 
generally should be deferred. …’
4. ‘If the balance of benefits and harms is uncertain, the provider should respect 
the decision of competent adolescents and their families.	These decisions should 
be based on the unique circumstances of each family. The provider should enter 
into a thorough discussion about the potential benefits and harms and should 
assess the family’s understanding of these issues.’
5. ‘Testing should be discouraged when the provider determines that potential 
harms of genetic testing in children and adolescents outweigh the potential 
benefits.	A health-care provider has no obligation to provide a medical service 
for a child or adolescent that is not the in the best interest of the child or 
adolescent.’
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3.9.10  The family’s involvement in decision-making
1. ‘Education and counseling for parents and the child, commensurate on 
maturity, should precede genetic testing. Follow-up genetic counseling and 
psychological counselling also should be readily available. Providers of genetic 
testing should be prepared to educate, counsel and refer, as appropriate.’
2. ‘The provider should obtain the permission of the parents and, as appropriate, 
the assent of the child or consent of the adolescent. …’
3. ‘The provider is obligated to advocate on behalf of the child when he or she 
considers a genetic test to be – or not to be – in the best interest of the child. 
Continued discussion about the potential benefits and harms – and about the 
interests of the child – may be helpful in reaching a consensus.’
3.9.11  Considerations for future research
 ‘As genetic testing for children and adolescents becomes increasingly feasible, 
research should focus on the effectiveness of proposed preventive and 
therapeutic interventions and on the psychosocial impact of tests. Such data are 
necessary to define the empirical benefits and harms of testing before judgments 
about the advisability of testing are formulated.’249
 
.0  american academy of Pediatrics, 200
The Report of the American Academy of Pediatrics (AAP), Ethical	 Issues	 with	
GeneticTesting	 in	 Pediatrics,250	 recommends that genetic testing for adult-onset 
conditions, when the genetic information has not been shown to reduce morbidity 
and mortality through interventions initiated in childhood, should be deferred ‘until 
adulthood or until an adolescent interested in testing has developed mature decision-
making capacities’.
.  european society of human genetics, 200
Recommendation 15 of the European Society of Human Genetics (ESHG) Report, 
Provision	of	Genetic	Services	in	Europe,251	would allow genetic testing of a minor if 
‘necessary for differential diagnosis of manifest symptoms or for establishing the 
cause of a disease’. Predictive genetic testing for childhood-onset conditions for 
which there are beneficial medical interventions is also indicated. However, ‘[o]ther 
predictive tests and tests for carrier status should be delayed until the person is old 
enough to make an informed decision’.
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.2  norway
The Act relating to the application of biotechnology in human medicine, etc. (5 
December 2003, No. 5), sections 5–7, ‘Genetic testing of children’,252 states that pre-
symptomatic, predictive and carrier testing shall not be carried out on children under 
the age of sixteen unless the test can detect a condition for which treatment may 
prevent or reduce damage to a child’s health. The Ministry may in special cases grant 
exemptions from the prohibition. The grounds upon which an exemption might be 
granted are not clear from the Act. 
.  world health organisation human genetics Programme, 
On the basis of the principles of autonomy, beneficence and non-maleficence, the 
World Health Organisation (WHO) issued its Proposed	International	Guidelines	on	
Ethical	Issues	in	Medical	Genetics	and	the	Provision	of	Genetic	Services, which state that 
‘Testing of children or adolescents should be carried out only if there are potential 
medical benefits to the child or the adolescent’.253
.  world health organisation human genetics Programme, 200
The World Health Organisation (WHO) Human Genetics Programme (HGP) Review	
of	 Ethical	 Issues	 in	 Medical	 Genetics comprises guidelines for testing children and 
adolescents. The guidelines primarily relate to children who cannot give informed 
consent, and recommend that:
•	 Testing for conditions for which preventive measures or treatment are available 
is ‘tantamount to diagnosis and should proceed according to consent guidelines 
established for other necessary medical interventions’.254 However, testing should 
not be offered before the earliest age at which health benefits accrue.
•	 Requests for carrier testing should be evaluated on an individual, case-by-case 
basis. 
•	 However, the harms of pre-symptomatic or susceptibility testing ‘would appear 
to outweigh any benefits’.
•	 ‘Testing in the absence of medical benefit or current reproductive benefit is 
usually best avoided. … Decisions that override parental autonomy may be 
necessary in order to prevent harm and to preserve a minor’s future autonomy, 
which should be the paramount considerations’.255
•	 In cases of testing solely for the benefit of another family member, such as 
linkage analysis, or to enable parents to use prenatal diagnosis in a subsequent 
pregnancy, ‘the test should have a clear usefulness for others, and the rationale 
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for the test, including the name and description of the disorder (but not the 
name of the person on whose behalf the minor is to be tested, except with that 
person’s permission) should be explained insofar as possible. The minor should 
have the opportunity to decide, upon reaching adulthood, whether to know or 
not know the results’.256 
The recommendations in the WHO documents are ‘intended as points of departure 
for genetics professionals and public health officials to develop policies and practices 
in their own nations’.257
.  Discussion
A number of recurring themes emerge from the professional position statements 
and guidelines in respect of genetic testing of minors who cannot give their own 
informed consent. 
All of the statements caution against genetic testing of children for late-onset disorders 
for which no pre-symptomatic medical interventions exist. A similarly cautionary 
stance is generally also taken in respect of carrier testing of children who cannot give 
their own informed consent. 
The guidance emphasises the paramountcy of the best interests of the child. However, 
timely medical benefit is seen as key. Whilst there is some acknowledgement of the 
psychosocial benefits that may arise from genetic testing of minors (more usually 
in the context of testing on a competent minor’s request), and an oft-expressed 
desire not to have a blanket policy (to allow for an individualised assessment of 
the benefits and harms potentially applicable in each case), the major focus is on 
clinical benefits or lack thereof. This is perhaps unsurprising given that most of the 
guidelines and position statements detailed were formulated by and for groups of 
health professionals. 
The principles of autonomy, non-maleficence and beneficence arise frequently in the 
position statements as being those most relevant to decision-making in respect of 
genetic testing of minors. 
Most of the statements take it for granted that predictive testing in childhood for a 
late-onset disorder, or carrier testing, infringes the minor’s autonomy. Robertson and 
Savulescu have argued that predictive testing of minors is not necessarily a violation 
of a child’s future autonomy, and may in fact facilitate the development of autonomy 
in a maturing child.258 This idea and their arguments are discussed in greater detail in 
the ‘Benefits and harms’	section of this report. 
Many of the more in-depth statements or guidelines list purported benefits and 
harms of genetic testing of minors, focusing on psycho-social consequences of 
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testing (as the focus of these statements is frequently on genetic testing for non-
medical reasons). Similar benefits and harms are catalogued by the various groups. 
The ASHG/ACMG ‘Points to Consider’	section	also offers some comments on the 
likely medical benefits and harms of genetic testing of minors, including prevention 
or treatment, and increased or reduced surveillance. 
Concerns about the minor’s right to confidentiality and possible discrimination 
are recurring motifs related to both autonomy and the wider benefits and harms of 
testing. 
Many statements lament the lack of evidence of the effects of genetic testing of 
minors. Some call for more empirical research to assess the benefits and harms 
consequent upon predictive testing, e.g. medical interventions, psycho-social benefits 
and harms and the effectiveness of non-medical interventions (such as training a 
child or adolescent for adult-onset blindness).259 When referring to purported harms 
of testing, some of the statements mention the body of evidence relating to predictive 
testing in adults for the HD mutation in particular, because of the lack of child-
specific evidence on the effects of genetic testing. 
Most sets of guidelines discuss the child’s interests within the milieu of the family. 
Recognition of the inseparability of the child from the family leads most of the 
professional bodies to recommend a non-adversarial, open, communicative and 
supportive approach to handling parental requests for genetic testing of minors. 
Particular emphasis is placed on genetic counselling of the parents and	 the child, 
in order to examine the consequences of testing for the particular child within the 
family context. Both the HGSA and the ASHG/ACMG guidance note that the role of 
the genetic counsellor is that of advocate for the child. 
Ideas about parental rights and responsibilities, and the evolution of the law in 
this respect (from parental rights to make all decisions for their children, to their 
responsibility to make decisions in their best interests), are prominent, particularly 
in the United Kingdom CGS report and the ASHG/ACMG ‘Points to Consider’. Most 
guidance, particularly that from GIG, recognises that parents generally do know and 
act in accordance with their children’s best interests.
The position statements refer varyingly to parental rights to make their children’s 
medical decisions, from mentioning non-specific legal limits on their rights (HGSA, 
CGS), to specific limits (ASHG/ACMG), to outright denial of their rights to make 
non-therapeutic medical decisions for children (CPS).
Although	 parents	 are	 the	 decision	 makers	 for	 their	 children’s	 therapeutic	
treatment,	 they	 do	 not	 have	 authority	 over	 non-therapeutic	 interventions,	
including	genetic	testing.260
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The nature or specifics of the genetic condition for which testing is sought does not 
always seem to be important, except to the extent that it is treatable or non-treatable. 
The focus in most statements is on testing for late-onset disorders, rather than 
those with childhood onset, even when the latter cannot be prevented or treated. 
Huntington disease is frequently used as the exemplar of an untreatable late-onset 
disorder for which children should not be tested. Thus it is frequently not clear to 
what extent any recommendations apply to genetic testing for untreatable childhood-
onset conditions. 
In terms of guidance on predictive testing compared to carrier testing, the HGSA 
has not promulgated guidelines on carrier testing and the ASHG/ACMG guidelines 
focus predominantly on predictive testing. The United Kingdom CGS report goes 
into both predictive and carrier testing in some depth, and seemingly treats carrier 
testing of minors with a little more leniency.
3.15.1  Systematic reviews of the guidelines
…	guidelines	should	always	be	assessed	in	the	particular	local	legal	context	and	
cannot	always	be	translated	to	another	cultural	setting.261	
Having conducted a systematic review of twenty-seven sets of professional guidelines 
or position statements on genetic testing of minors, from thirty-one different 
organisations (issued between 1991–2005), Borry et al. conclude that there is a 
remarkable degree of unanimity:262
The	 main	 justification	 for	 presymptomatic	 and	 predictive	 genetic	 testing	 was	
the	direct	benefit	to	the	minor	through	either	medical	intervention	or	preventive	
measures.	 If	 there	 were	 no	 urgent	 medical	 reasons,	 all	 guidelines	 recommend	
postponing	 testing	 until	 the	 child	 could	 consent	 to	 testing	 as	 a	 competent	
adolescent	or	as	an	adult.	Ambiguity	 existed	 for	 childhood-onset	disorders	 for	
which	preventive	or	therapeutic	measures	are	not	available	and	for	the	timing	
of	 testing	 for	 childhood-onset	 disorders.	 Although	 the	 guidelines	 covering	
presymptomatic	 and	 predictive	 genetic	 testing	 of	 minors	 agree	 strongly	 that	
medical	benefit	is	the	main	justification	for	testing,	a	lack	of	consensus	remains	
in	 the	 case	 of	 childhood-onset	 disorders	 for	 which	 preventive	 or	 therapeutic	
measures	are	not	available.263
Many of the guidelines that Borry et al. reviewed did not distinguish between 
genetic testing for early-onset or late-onset disorders. Of those that did not make 
the distinction, the consensus was that predictive testing should only be undertaken 
with persons legally competent to make their own decisions, unless preventative or 
therapeutic actions could be initiated as a result of testing. 264 
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The failure to differentiate between testing for early-onset versus late-onset disorders 
was notable because different issues arose as a consequence of each kind of testing, 
which might lead to different recommendations being offered (particularly where 
there were no medical interventions available). Borry et al. suggest that the lack of 
differentiation may have been as a result of an early focus on adult-onset conditions 
(HD in particular), or because there may have been difficulties in reaching consensus 
in respect of testing for early-onset conditions. 265 
The eleven position statements that did differentiate between early and late-onset 
testing made the same recommendation in respect of predictive testing for late-
onset conditions. However, it was ‘less clear for childhood-onset disorders for which 
preventive or other therapeutic measures are not available’.266 Five of the statements 
considered genetic testing of minors appropriate in these circumstances because of 
the importance of parental discretion, given the uncertainty about the benefits and 
harms. That is, genetic testing of minors was permitted if there were useful medical 
interventions available or	the condition was early onset (only one of the criteria need 
be met). 




Borry et al. note that genetic testing of minors for early-onset conditions for non-
medical reasons would not occur if the same rationale requiring clinical benefits 
were applied as is applied to testing for late-onset disorders.268 
Borry et al. note that there are more professional guidelines or position statements 
on predictive testing of minors than there are about carrier	testing. They reviewed 
fourteen sets of professional policies or guidelines in respect of carrier testing, 
from twenty-four different organisations.269 Borry et al. intimate that there may be 
more statements on predictive testing because there is more consensus in respect of 
predictive testing, or because it is considered more controversial and ‘in greater need 
of clear recommendations’.270
All of the position statements that they reviewed in respect of carrier testing 
recommended that carrier testing not be performed on children and that it be deferred 
until the child could give informed consent to testing. However, the guidelines varied 
in their statements on: ‘(a) the role of genetic services in ensuring that children are 
informed about their carrier status and associated risks when they are older; (b) 
exceptions to the general rule of withholding or deferring carrier testing; and (c) the 
communication of incidentally discovered carrier status’.271
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Borry et al. contend that the child’s autonomy and right to make the decision about 
testing was the primary ethical principle at stake in the guidelines on carrier testing. 
Carrier testing could be deferred because it only affected the future of the child 
concerned and not her parents or guardians. Some guidelines also noted that the 
child’s right to the confidentiality of the information would also be infringed by 
being tested as a child.272
Despite	 the	 lack	 of	 conclusive	 evidence	 that	 carrier	 testing	 performed	 during	
childhood	harms	 children	psychologically,	 the	great	majority	of	 genetic	 testing	
guidelines	 espouse	 the	 premise	 that	 carrier	 testing	 might	 be	 detrimental	 to	




A few of the statements reviewed suggested that children could be carrier tested if 
this were the only way to discover critical information that would medically benefit 
a relative. However, the BMA and GIG statements presented a more flexible view of 
the testing of children:
These	two	guidelines	primarily	focused	on	family	dynamics	and	the	individual	








the	 child	 and	 his	 family	 than	 would	 complying	 with	 the	 request.	 Both	 stated	
that	having	knowledge	early	on	of	one’s	carrier	status	could	help	a	child	to	cope	
with	 this	 information	starting	 in	childhood	and	could	reduce	 the	anxiety	and	
uncertainty	experienced	by	parents	about	their	child’s	carrier	status.274	
Most of the guidelines did not deal with informing children of their risk status. 
The assumption seemed to be that ‘parents, being inherently responsible for the 
welfare of their children, are also responsible for informing their child of his genetic 
risk’.275 However, the United Kingdom CGS ‘assigned a clear responsibility to genetic 
counsellors, stressing that it is the responsibility of both the family and the healthcare 
system to ensure that carrier testing is offered when the child is older’.276 
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3.15.2  Comments
The position statements and guidelines reviewed above, and those reviewed by 
Borry et al., take a generally prohibitive stance towards genetic testing of minors 
(who cannot give their own informed consent) for untreatable late-onset disorders. 
Medical benefits comprise the main justification for any genetic testing of children, 
although special circumstances in which testing may result in other psycho-social 
benefits that outweigh harms are also considered. There is some ambiguity about 
the approach to be taken to parental requests for genetic testing for early-onset 
conditions for which no prevention or treatment is available. There appears to be less 
consensus and there are certainly fewer recommendations in respect of carrier testing 
of minors. Those recommendations that exist appear to take a slightly more lenient 
view of such testing than of predictive testing for untreatable late-onset disorders. 
.  competent minors
What do the various professional guidelines and position statements on genetic 
testing of minors say about the ability of competent minors to consent to testing?
3.16.1  New Zealand
There is a clear cautionary stance in the New Zealand Independent Biotechnology 
Advisory Council statement that ‘the testing of children is generally not considered 
appropriate unless the child will directly benefit from the results of the test,’277 but 
no reference to the age at which a child might be able to make the decision regarding 
testing for him or herself.
The Central Regional Genetics Services Protocol	 for	 Pre-Symptomatic,	 Diagnostic,	
and	Prenatal	Testing	for	Huntington	Disease (2001) contains the following statements 













3.16.2  Human Genetics Society of Australasia, 2005
The Predictive	 Testing	 in	 Children	 and	 Adolescents	 2005	 policy acknowledges that 
different states and territories within Australasia stipulate different ages at which 
individuals assume personal responsibility for their own health care. Thus while the 
thrust of the guidelines’ recommendations apply to those under the age of eighteen, 
the policy recognises that legislation in some regions permits children to make 
independent health-care decisions at a younger age. The policy further specifies that 
prior to the statutory	age at which independent health-care decisions can be made, 
a child’s parents have the legal authority to make medical decisions on behalf of 
the child. 
Section 36(1) of the Care of Children Act 2004 permits sixteen and seventeen-year-
old minors in New Zealand to make independent health-care decisions. Note that the 
HGSA policy refers to ‘legislation’ and the ‘statutory’ age at which a person can make 
health-care decisions. In New Zealand, the Code of Health and Disability Services 
Consumers’ Rights and Gillick278	 give the same right to minors under the age of 
sixteen who are competent to make their own medical decisions. 
The HGSA policy states that when a child under the age of eighteen (or the statutory 
age of consent)279 requests predictive genetic testing for a late-onset disorder, the 
health professional must seek to establish whether the child is competent to make an 
appropriate decision regarding the test, and outlines points to consider when assessing 
competence (including consultation with medical geneticists, genetic counsellors 
and psychologists). 
The policy appears to support predictive genetic testing of minors under the statutory 
age of consent who request testing, provided that the minor is competent to make an 
appropriate decision.280 
Autonomy is categorised as one of the underlying ethical principles in respect of 
predictive testing in children.281 It acknowledges that some adolescents have ‘sufficient 
maturity’ to make their own decisions about predictive testing. Thus there is a need 
for flexible consideration of the age at which children and adolescents will be ready 
for information which will help them in decision-making about testing.
The policy recommends that parents be encouraged to inform their children, ‘at 
an appropriate age, of the genetic condition in the family and the implications’ 
so that the child can be raised with knowledge. The policy also states that	genetic 
counselling, using language and terminology that can be readily understood by the 
child and parents, is an essential prelude to predictive genetic testing. When parents 
and the minor are in conflict, the counsellor should act as an advocate for the minor, 
whilst recognising that the minor is part of the family. Counselling needs to focus on 
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the family and child both together and separately, and it must be recognised that a 
child may not be able to exercise free choice in the face of strong parental opinions 
or discord.
Carrier testing is not specifically mentioned by the HGSA guidelines, which focus 
on predictive testing of minors. There are no HGSA guidelines on carrier testing of 
minors. There thus appears to be no New Zealand-specific professional guidance 
on carrier testing of minors. However, the same principles as those espoused in the 
HGSA policies on predictive testing presumably apply. 
The HGSA policies state that predictive genetic testing of minors under the age of 
eighteen should generally be restricted to testing which has a direct medical benefit 
to the child. However, both policies explicitly note that there may be relevant law that 
takes priority over statements in the policy: ‘allowance must be made for legislation 
… which permit independent healthcare decisions to be made at a younger age’. 
Thus, those of or over the age of sixteen in New Zealand can consent to or refuse to 
consent to predictive genetic testing pursuant to the HGSA policy (and section 36(1) 
of the Care of Children Act 2004).
The Predictive	 Testing	 in	 Children	 and	 Adolescents	 policy acknowledges that some 
adolescents may have sufficient maturity to make their own decision about predictive 
testing and sets out guidance for health professionals in assessing the competence of 
a child under the statutory age of consent to make an ‘appropriate’ decision regarding 
testing. The HGSA policy therefore permits minors under the age of sixteen to 
consent to and refuse to consent to genetic testing if they are competent to consent 
(in line with our statutory, regulatory and common law as discussed later). 
3.16.3  Other jurisdictions
Further guidelines, position statements, policies and recommendations are not 
necessarily applicable to New Zealand health professionals, but they may be 
persuasive, and they provide a wider context regarding the way in which requests by 
competent minors are to be viewed in the clinical genetics setting. 
The ASHG/ACMG Report, Points	 to	 Consider:	 Ethical,	 Legal,	 and	 Psychosocial	
Implications	of	Genetic	Testing	in	Children	and	Adolescents,	1995,282	frequently refers 
to the importance of listening to and taking into account the views of competent 
minors. Indeed, most of the ‘Points to Consider’, recorded at the outset of the 
document, refer to the need to consider testing requests from competent minors. 
There is a heavy emphasis throughout the Report on respecting such requests. 
The Report opines that there might be ‘strong psychological and philosophical 
justifications for a more nuanced understanding that grants some level of decision-
making authority to children < 18 years of age’.283 It recognises that, as decision-
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making capacity increases, greater consideration should be given to the child or 
adolescent’s wishes, regardless of whether they accord with their parents’ wishes, or 
their own best interests, and that minors might have a genuine interest in career or 
child-bearing choice, despite their still being vulnerable to coercion, stigmatisation 
and altered self-image.284
There are additional considerations when adolescents themselves request genetic 
testing. For example, if an adolescent requests a predictive HD test the provider must 
question whether the request is coming from the adolescent or the parent. Where 
there are uncertain benefits and harms there must be individual assessment of 
competence and voluntariness.285 
Carrier testing is not a specific focus of the ASHG/ACMG ‘Points to Consider’. The 
Report does mention that the reproductive benefits of genetic testing are of minimal 
value to children – even to sexually active adolescents, who are apparently unlikely 
to make family-planning decisions primarily on the basis of their genetic status.286 
However, the Report states that exceptions to the principle of deferring carrier testing 
‘might occur when the adolescent meets conditions of competence, voluntariness, and 
adequate understanding of information’.287 More generally, the ‘Points to Consider’ 
can be applied to decision-making regarding carrier testing.
As with the HGSA guidelines, the ASHG/ACMG Report stipulates that the primary 
goal of genetic testing should be to promote the well-being of the child. This primary 
goal could justify the genetic testing of a competent minor upon request, in order to 
alleviate anxiety and uncertainty, and to enable better decision-making:
Substantial	 psychosocial	 benefits	 to	 the	 competent	 adolescent	 also	 may	 be	 a	
justification	for	genetic	testing.	The	benefits	and	harms	of	many	genetic	tests	are	
psychosocial	 rather	 than	 physical.	 Relevant	 issues	 include	 anxiety,	 self-image,	
uncertainty,	 and	 the	 impact	 on	 decisions	 relating	 to	 reproduction,	 education,	
career,	insurance,	and	lifestyle.288
However, there is also a great deal of vacillating between the requirement of ‘primum	
non	nocere’ (‘do no harm’, see point 5 under ‘Points to Consider’) and the evident 
importance of respecting the increasing competence and autonomous choices of 
minors. This irresolution is perhaps to be expected given that the Report is not a set 
of guidelines or standards for clinical practice; it sets out points to consider regarding 
the ethical, legal and psychosocial implications of genetic testing of minors. It gives 
providers a starting point for acknowledging, and discussing with minors, parents 
and families, the ethical implications of testing. The final decision regarding whether 
or not to respect a competent minor’s request for predictive genetic testing clearly 
may depend on a range of factors, and will be for the provider to decide, with the 
assistance of other professionals where necessary. 
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Alternatively, the oscillation between the principle of non-maleficence and respect 
for autonomy may result from the failure to distinguish clearly at which point the 
Report is referring to testing of younger children on the basis of parental consent, 
and when it is referring to requests by competent minors e.g. ‘… the provider’s 
guiding principle continues to be primum	 non	 nocere – first do no harm. Thus, 
when faced with uncertainty, the provider may be obligated to avoid the possibility 
of harm, rather than to provide unclear benefits. … On the other hand, in specific 
cases where the benefits and harms … are more uncertain, more weight should be 
given to the wishes of the competent adolescent’. The first part of this paragraph 
may well be referring to testing upon parental request, when the benefits and harms 
are uncertain, and the latter part to testing upon an adolescent’s request when the 
benefits are uncertain. 
The AAP statement, Ethical	 Issues	 with	 Genetic	 Testing	 in	 Pediatrics,289 does not 
support ‘the broad use of carrier testing or screening in children or adolescents’. 
However, it states that carrier testing for pregnant adolescents or others who are 
planning pregnancy might be appropriate if they have been fully informed of the 
benefits and risks of testing. 
The United Kingdom CGS Working Party report, the Genetic	Testing	of	Children,290 
focuses predominantly on genetic testing in younger children. However, it clearly 
states that a child below the statutory age of consent will be able to give consent on 
the child’s own behalf if the test and its significance can be understood.291 
The Working Party observed that there had been significant recent relevant 
developments in child law. Most notable were the case of Gillick292 and the Children 
Act 1989, both of which had considerably altered the legal status of children. 
The	 courts	 have	 suggested	 that	 children	 should	 be	 given	 the	 chance	 to	 take	
decisions	on	medical	care	for	themselves	if	it	is	possible	to	wait	until	they	are	able	
to	do	so	without	risking	their	health.293	
Older children can give their own consent if they have sufficient understanding of 
the issue to make a choice: Gillick and section 2(4) of the Age of Legal Capacity 
(Scotland) Act 1991. There is a statutory presumption that children of sixteen have 
sufficient capacity: section 8, Family Law Reform Act 1969 and section 1, Age of Legal 
Capacity (Scotland) Act 1991. If a minor below that age can understand a test and its 
significance then that minor will also be able to give consent.294 
The Report goes on to highlight the fact that the English Courts had recently held that, 
even when a child was mature enough to give consent, parents could still authorise 





The United Kingdom CGS Working Party Report considers that carrier testing can 
usually be deferred without any penalty to allow the minor eventually to participate 
in the decision as an autonomous person. It too states that sexual activity is not a 
reason for genetic testing and that it should not be assumed that a pregnant teenager 
at risk for being a carrier would want carrier testing and possible prenatal testing. 
The Report recommends raising the question of genetic risk with the adolescent 
either within the family setting or through their family doctor, and that a referral be 
arranged for genetic counselling when and if the minor so chooses. ‘To push such 
counselling or testing upon an adolescent (or anyone) is unacceptable, and it is likely 
to generate more problems than it “solves”.’297 The Report also recommends that, 
like all adolescents, adolescents who may be carriers should be fully informed about 
human reproduction and contraception. 
The United Kingdom Joint Committee on Medical Genetics recently endorsed the 
United Kingdom CGS recommendation that testing for adult-onset disorders or 
carrier testing should be postponed until the child demonstrates Gillick-competence 
to make a decision.298 
The GIG Response	to	the	Clinical	Genetics	Society	Report299	indicated that the issue of 
‘how to draw a dividing line between childhood and adulthood, and the consequences 
this might have for issues related to the genetic testing of children’ was an issue in 
need of further consideration. GIG suggested that the age at which minors became 
sexually active might be a better indicator than any fixed age: ‘It is certainly the age at 
which genetic information becomes important in many circumstances’. 300
With regard to predictive testing for adult-onset conditions in particular, GIG 
considers that the rights of the affected individuals to make an informed choice at 
a later date have to be held paramount. It does not elaborate further as to the age 
at which individuals may be able to make such an informed choice. However, the 
response does note that in their experience ‘children can cope with information 
about themselves from an early age and that it is much more often the adult who has 
a problem in giving information’. 301
In contrast to the United Kingdom CGS, the GIG considered that in many or even most 
cases the issue of carrier status will be best dealt with at puberty or when the minor 
becomes sexually active. ‘The child, or young adult, as s/he will then be, would discuss 
the issues with parents and professionals, and make a decision based upon this.’302
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The Nuffield Council on Bioethics 1998 Report, Mental	Disorders	and	Genetics	Ethical	
Issues, noted that section 8(1) of the Family Law Reform Act 1969 allowed minors of 
sixteen and seventeen years of age to give valid consent to ‘treatment’ as if they were 
adults: ‘It is probable that only diagnostic testing and perhaps, very rarely, carrier 
detection would be so regarded’.303
The Council suggested that predictive genetic testing:
may	fall	in	a	novel	category	raising	such	complex	issues	of	benefit	and	possible	





In its conclusions and recommendations the Council states that the issues raised in 
the context of genetic testing for children able to give consent to medical treatment 
are comparable to those for adults. However, for genetic testing that could not be 
considered medical treatment, the Council considered that it was unclear whether 
those under sixteen, in particular, would be regarded as being able to give valid 
consent to testing.305
The ACGT Report	on	Genetic	Testing	for	Late	Onset	Disorders	(1998)	stated that:
Requests	 for	 adolescents	 themselves	 regarding	 presymptomatic	 genetic	 testing	
of	late	onset	disorders	deserve	full	and	sensitive	discussion,	taking	into	account	
the	 individual	and	 their	 family.	 If	 the	adolescent	 is	 competent	 to	give	 consent	




The ACGT (now subsumed by the HGC) noted that adolescents would greatly vary 
as to their emotional and mental maturity regarding complex issues for later life. 
While currently requests from adolescents were rare, they required full discussion 
with an experienced professional. Certain situations in which testing of adolescents 
upon request needed to be considered included pregnancy; testing for FAP; and 
testing for disorders such as familial cardiomyopathy where there may be a history 
of sudden death in young family members. ‘The situation for each disorder requires 
careful consideration.’307
The CPS Guidelines	for	Genetic	Testing	of	Healthy	Children308 state that full understanding 
of the nature and consequences of agreeing to or refusing medical management does 
not occur until early adolescence, or later. The capacity to understand abstract ideas 
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of social risk, including loss of privacy, social stigmatisation and potential insurance 
or employment discrimination may require even greater insight. It is also noted that 
many adults have difficulty understanding probability and risk in terms of genetic 
test results.309 The Guidelines acknowledge that ‘It does not seem justified, however, 
to refuse testing to a fully informed, competent adolescent who is requesting it’,310 
and that restricting predictive testing to persons of or over the age of eighteen might 
infringe individual rights and threaten reproductive autonomy.311
The Guidelines recommend that: 




The CPS Guidelines	for	Genetic	Testing	of	Healthy	Children	caution that despite the 
perception that carrier testing may be of low risk because the person tested will not 
manifest the disorder ‘the child’s right to future reproductive privacy is an important 
consideration’.313
No age brackets are given in terms of when children might become competent; it is 
merely noted that ‘full understanding of the nature and consequences of agreeing to 
or refusing medical management does not occur until early adolescence, and maybe 
later’. It is thus a maturity or understanding-based competency test. The premise 
that ‘The ability to understand the abstract concepts of social risk, including loss of 
privacy, social stigmatization and potential employment or insurance discrimination 
may require even more sophistication’ is questionable. Adolescents of high school age 
may well understand the risks involved in loss of privacy and the concept of social 
stigmatisation, given the environments in which they exist. Health professionals must 
assess the minor’s competence as an individual and not on a generic concept of what 
minors are presumed to understand or not understand.
The CCMG Position	Statement	on Genetic	Testing	of	Children supports the principles 
outlined in the ASHG/ACMG ‘Points to Consider.’ It further adds that ‘The age at 
which a child may be offered the test can be the age of responsible understanding, 
rather than the age of majority’,314 explicitly acknowledging that a competency-based 
assessment of minors is the appropriate approach.
In Norway, the law prohibits pre-symptomatic, predictive and carrier testing of 
children under the age of sixteen unless the test can detect a condition for which 
treatment may prevent or reduce damage to a child’s health.315 The Ministry may in 
special cases grant exemptions from the prohibition. Predictive testing of children for 
non-medical reasons is thus against the law in Norway, unless one has an exemption 
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from the Ministry. It is unclear from the Act whether a competent minor might be 
able to get an exemption.
Recommendation 15 of the ESHG 2001 Report, Provision	 of	 Genetic	 Services	 in	
Europe,316 would allow genetic testing of a minor if ‘necessary for differential diagnosis 
of manifest symptoms or for establishing the cause of a disease’. Predictive genetic 
testing for childhood-onset conditions for which there are beneficial medical 
interventions is also indicated. However, ‘Other predictive tests and tests for carrier 
status should be delayed until the person is old enough to make an informed decision’. 
There is no reference to the need for the person to have reached a statutory age of 
majority – the test is competency based. Therefore, presumably, pursuant to the ESHG 
policy a competent minor could give informed consent to a predictive genetic test.
The 1998 WHO Human Genetics Programme Proposed	International	Guidelines	on	
Ethical	Issues	in	Medical	Genetics	and	the	Provision	of	Genetic	Services	state that, on 
the basis of the principles of autonomy, beneficence and non-maleficence, ‘Testing 
of children or adolescents should be carried out only if there are potential medical 
benefits to the child or the adolescent’. However, the document does note that 
‘presymptomatic or susceptibility tests for adult-onset disorders are usually best 
postponed until adulthood, when the young adult can make her/his own decision’, 
arguably leaving room for a competent minor to make the decision.317
The guidelines for testing children and adolescents in the 2003 WHO Human 
Genetics Programme Review	of	Ethical	Issues	in	Medical	Genetics	primarily relate to 
children who cannot give informed consent. With respect to older children:
If	the	law	permits	testing	of	minors,	the	minor	should	be	the	primary	decision-
maker.	Professionals	should	probe	to	discern	whether	the	minor	is	acting	on	her/





This is a more cautious approach to testing of competent minors than is seen in most 
of the other guidelines and position statements. However, the recommendations in 
the WHO documents are ‘intended as points of departure for genetics professionals 
and public health officials to develop policies and practices in their own nations’.319
.7  Discussion
All of the guidelines and policies that we have read make a clear distinction between 
predictive testing of minors for conditions for which there are medical benefits 
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available, and those for which there are not. Most of them recommend that genetic 
testing for conditions for which there are no beneficial medical interventions available 
in childhood should generally be deferred until majority. However, despite the claim 
that ‘opposition … exists as the default position in existing guidelines’,320 most of 
the more prominent guidelines are receptive to the possibility of competent minors 
requesting and giving informed consent to predictive genetic testing. 
The guidelines generally do not explicitly state an age at which competent minors 
may make such decisions. The lack of an arbitrary stipulated age is to be expected 
and commended given the emphasis on competence and maturity-based assessment 
of minors, which is in line with the principles of UNCROC, Gillick, and our Code 
of Health and Disability Services Consumers’ Rights (all of which are discussed in 
detail later).
Some of the guidelines and position statements are explicit in their support for the 
competent minor’s ability to make decisions in respect of genetic testing, most notably 
the CCMG, CPS and United Kingdom CGS guidelines, and the United Kingdom 
ACGT Report	on	Genetic	Testing	for	Late	Onset	Disorders. However, comments relating 
to competent minors are often in the commentary or discussion on the guidelines 
or recommendations, rather than in the actual recommendations themselves. This 
is presumably because the focus is usually on testing of minors who cannot give 
informed consent. 
The systematic review of twenty-seven papers dealing with guidelines or position 
papers on predictive genetic testing of minors conducted by Borry et al. revealed not 
only ‘a remarkable degree of unanimity’321 but also a finding that no guidelines used 
a person’s eighteenth birthday as a ‘strict rule for accepting or refusing genetic testing 
for adult-onset disease’.322 All of the guidelines emphasised that age should be given 
flexible consideration, and that genetic testing should be deferred as far as possible 
until minors were competent to make their own informed decisions. However, ‘several 
guidelines recommend that assessments of competence and maturity in young people 
should be made, but little advice is given about how to make such assessments’,323 
except for rather vague allusions to, for example, ‘the degree of maturity and state of 
development’ of the minor.324 
In many of the guidelines and statements there is clear support for carrier testing 
of adolescents who are making reproductive decisions, or who are already pregnant 
(although the United Kingdom CGS Report cautions against assuming that at-risk 
pregnant teenagers will want carrier testing and prenatal testing).
As discussed in the section on genetic testing of minors who cannot give a valid 
consent, Hogben and Boddington take issue with the distinction frequently drawn 
between testing minors for carrier status, and testing them for late-onset disorders.325 
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Borry et al. note that: 









Borry et al. also recently conducted a systematic review of guidelines and position 
papers relating to carrier testing.327 In contrast to Hogben and Boddington’s argument 
that autonomy takes a backseat to concerns about benefits and harms in the carrier-
testing discourse,328 Borry et al. identified the child’s future autonomy as the main 
ethical argument at stake in the fourteen sets of guidelines on carrier testing that 
they analysed. 
They stated that all guidelines agreed implicitly that eighteen years of age represented the 
legal borderline between childhood and adulthood, while noting that many guidelines 
also drew a distinction between childhood and adolescence (without attaching specific 
ages to the distinction). The differences that distinguished children from adolescents 
included the gradual development of cognitive skills and moral reasoning, and 
increasing capacity for participation in decisions about their own welfare.329 
Adolescents who met various tests of competence, voluntariness and adequate 
understanding; decision-making capacity; maturity to take control of their own 
health care; or ability to participate in decision-making as autonomous individuals 
were considered competent to request a carrier test. There was also a strong sense 
that the minors should have parental support in their decision.
Borry et al. concluded that: 
…	 all	 guidelines	 recommend	 delaying	 carrier	 testing	 until	 the	 minors	 can	
participate	 themselves	 in	 these	 decisions	 that	 are	 affecting	 them.	 Several	
guidelines	state	that	minors	could	request	a	carrier	test	from	the	moment	they	
meet	conditions	of	competence	and	have	decision-making	capacity.330	
The guidelines outlined earlier (and those considered by Borry et al.) do not appear 
to treat carrier testing less seriously than predictive testing, at least in respect of 
competent minors. Carrier testing of minors is generally advised against, and the 
same threshold of competence must be met before minors can give their own consent 
to testing. 
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There are some differences amongst the guidelines regarding whether puberty 
or the time at which a minor becomes sexually active is an appropriate time for 
minors to be able to give their own consent in respect of carrier testing, given that 
genetic information about carrier status is almost exclusively related to reproductive 
concerns. Some statements (e.g. from the AAP and GIG) explicitly note that carrier 
testing should be provided when the child is becoming sexually active or making 
reproductive decisions. Others (ASHG/ACMG and CGS) consider that sexual activity 
is not a reason for carrier testing per	se. 
It is important to note that minors at risk for late-onset disorders are also at risk 
for passing a genetic mutation on to their offspring. Any argument that sexually 
active minors must be able to access carrier testing would also justify their access to 
predictive testing.
.  conclusion
The HGSA guidelines, Predictive	 Testing	 in	 Children	 and	 Adolescents, would allow 
competent minors in New Zealand to give informed consent to predictive genetic 
testing. Given that there is no professional guidance in respect of carrier testing 
in New Zealand, presumably the same principles as those espoused in the HGSA 
guidelines would apply. 
Many of the other prominent position statements and guidelines from professional 
groups in other jurisdictions also provide that minors can make their own decisions 
about genetic testing, provided that they meet varying standards of competence, 
understanding and voluntariness. Arbitrary age restrictions are rarely set down. 
Given that genetic testing of children is seldom legislated against but that professional 
groups recommend against it, what evidence is there of particular attitudes towards 
genetic testing of minors, and what evidence is there of particular professional practice? 
We next examine professional practice and the attitudes of health professionals and 
other groups in respect of genetic testing of minors, in the context of the genetics 
services and testing milieu in New Zealand. 
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.  introduction 
Unsurprisingly, given the dearth of evidence regarding the effects of genetic testing 
of minors,332 there is a not a great deal of evidence about professional practice 
in relation to such testing. However, a few overseas studies from the past decade 
and a half have revealed conflicting information about different groups of health 
professionals’ attitudes, awareness and practice in terms of genetic testing of children, 
despite international and national guidelines against screening children for late-onset 
conditions with no effective medical management. For example,
Recent	work	demonstrates	that	pediatricians	appear	to	be	relatively	receptive	to	
parents’	wishes,	while	many	geneticists	express	more	caution	about	performing	
tests	 that	 will	 not	 yield	 information	 needed	 for	 the	 immediate	 medical	
management	for	the	child.333	
.2  attitudes regarding genetic testing of minors
There is a great deal more information about professionals’ and others’ attitudes 
regarding genetic testing of minors than there is about the practice of testing. 
.  international survey by Duncan et al
Duncan et al., in a discussion about predictive genetic testing of young people for 
non-medical reasons,334 noted that almost half (45 per cent) of the professionals who 
indicated that they had performed a predictive genetic test on a minor under the 
age of fourteen years for non-medical reasons cited the parents’ desire to know as 
the main reason for testing (45 per cent). A further three clinicians (14 per cent) 
indicated that the opportunity for planning was a reason for their provision of the 
test to the child.335
The most common reason articulated for providing predictive genetic tests for non-
medical reasons to a minor aged fourteen years or over was to resolve uncertainty 
for the young person (thirteen respondents (48 per cent) cited this as a reason). A 
further six respondents (21 per cent) indicated that the opportunity for planning 
was a reason for their providing the test to the minor. Two clinicians (7 per cent) 
provided tests (on parental request) because of parental anxiety, and two (7 per cent) 
tested for reproductive reasons.
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More than half of the respondents (53 per cent, or 159) had refused to perform 
a predictive genetic test, for non-medical reasons, on more than eight hundred 
occasions. Many clinicians gave more than one reason for refusing to test. Reasons 
included to protect the autonomy of the young person (n=75, or 47 per cent); testing 
did not provide a medical benefit (n=53, or 33 per cent); the possibility of harm 
(n=23, or 14 per cent); counselling had resolved the issue (n=8, or 5 per cent); and 
eight respondents (5 per cent) cited policy as a reason for refusing testing. One cited 
privacy as the main concern in refusing testing.
Duncan et al. questioned respondents as to how much they agreed with the existing 
guidelines concerning predictive genetic testing in young people. Just over a third 
of the respondents (104 or 35 per cent) strongly agreed with the guidelines, 141 (47 
per cent) agreed, 15 (5 per cent) disagreed, 5 (2 per cent) strongly disagreed, 10 (3 
per cent) indicated that they did not know, and 26 (9 per cent) did not answer the 
question.336
Of the 230 respondents who gave reasons for their views, 99 (43 per cent) cited 
the need to consider each case individually as a justification for the extent of their 







Eighty-eight respondents (38 per cent) commented that the need to protect autonomy 
was a justification for their view, 74 (32 per cent) cited the weighing up of benefit and 
harm, and 34 (15 per cent) cited the logic of the guidelines. For example,
The	 guidelines	 are	 well	 written,	 make	 sense	 and,	 in	 my	 opinion,	 promote	 the	
welfare	of	children,	families	and	communities.338	
Nine respondents (4 per cent) felt that it was inappropriate for clinicians to make 
the decisions about testing, as opposed to the family making the decisions: ‘Refusing 
testing is paternalistic’.339
Wertz documents results from a thirty-seven nation survey of 2903 geneticists, and 
surveys of 499 United States primary care physicians, 409 parents visiting genetics 
clinics in the United States and 988 members of the United States public. 340 
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Of the 2903 geneticists who responded to the survey, 1084 were from the United States. 
In terms of the United States views, large majorities of geneticists (81 per cent), the 
primary care physicians (89 per cent), parents (93 per cent) and the general public 
(84 per cent) considered that parents should be able to have their children tested 
for familial hyper-cholesteroleamia. Likewise a significant majority of each group 
thought that parents should be able to have their children tested for susceptibility to 
inherited cancers: 70 per cent of geneticists; 81 per cent of primary care physicians; 
93 per cent of parents; and 84 per cent of the public.
Around half of the geneticists (48 per cent) would allow parents to test their children 
for predisposition to alcoholism, whilst three quarters (76 per cent) of the primary 
care physicians would give parents that right. Just 27 per cent of the geneticists would 
allow parents to have their children tested for the HD mutation, compared with 66 
per cent of the primary care physicians. Only a quarter (25 per cent) of the geneticists 
would allow parents to have their children tested for predisposition to Alzheimer’s 
disease, compared with 58 per cent of primary care physicians, 62 per cent of parents 
and 53 per cent of the public.
These	 results	 point	 to	 a	 dichotomy	 between	 geneticists	 and	 the	 rest	 of	 the	 US	
medical	community,	whose	views	closely	paralleled	those	of	their	patients.341	
In terms of reasons given for their answers, 66 per cent of respondents indicated 
that a desire to avoid harm was important, whether through early treatment or 
prevention, or by protecting a child from potentially damaging knowledge about 
risk status. Other reasons included making the information available for decisions 
about medical management (43 per cent); protecting the child’s autonomy (25 per 
cent); respecting parental autonomy (13 per cent); believing that there was no need 
to know at this time (13 per cent); preparing for the future (9 per cent); and avoiding 
the possibility of stigmatisation (3 per cent).342 
There was a marked difference in geneticists’ willingness to test between the United 
States, other English speaking nations and Northern and Western Europe, and other 
regions such as southern and eastern Europe, the Near East, Latin America and Asia. 
The majority of geneticists from the latter regions think that parents should be able 
to have their minor children undergo predictive testing for HD, Alzheimer’s disease, 
alcoholism, cancer genes and familial hypercholesterolaemia. ‘Willingness to test in 
these regions appears to stem from cultural beliefs about the rights of parents and 
their authority over their children.’343 
Geneticists from the United States indicated more agreement with parental rights to 
have their children tested for HD, Alzheimer’s disease and alcoholism than geneticists 
from the other English-speaking countries. This result was partly as a result of the 
very low number of United Kingdom geneticists who indicated that they would test 
minors for these conditions.
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With respect to the geneticists from the English-speaking countries (United States, 
Australia, Canada, South Africa and the United Kingdom), the Australian and United 
Kingdom geneticists were more likely to have received a request to test a minor for a 
late-onset disorder than geneticists from the other nations. Wertz suggests that this 
greater experience with testing requests may have partly contributed to the greater 
reluctance of United Kingdom geneticists to accede to parental requests for testing. 
The opinions of geneticists, both from the United States and the United Kingdom, 
and primary care physicians from the United States, were reasonably evenly divided 
about whether to wait until the child reaches the legal age of majority to tell him or 
her about the genetic test results (except that 73 per cent of United States primary 
care physicians favour telling a child before the age of majority). Generally speaking, 
fewer parents than providers would tell children about test results before the age of 
majority (54 per cent for familial hypercholesterolaemia, and 47 per cent for cancer 
susceptibility). 
Wertz notes that ‘These responses appear to be somewhat contradictory to the stated 
purpose of testing, which is to begin treatment or monitoring early. If not told, the 
child may wonder about the purpose of medication, diet or medical testing’.344
Only a minority (41 per cent United States, 20 per cent United Kingdom) of the 
geneticists would tell a minor about his or her predisposition to alcoholism before 
the age of majority, while the majority of primary care physicians (68 per cent) would 
inform a minor before that time. Most geneticists would also not inform children 
of the results of HD or Alzheimer’s disease testing before the age of majority: just 
12 per cent of United Kingdom geneticists would inform minors of either of the 
test results before majority and, of United States geneticists, just 20 per cent would 
inform a minor of an HD test result, and 18 per cent would inform a minor about an 
Alzheimer’s disease test result before majority (compared to 44 per cent and 46 per 
cent of primary care physicians for the respective disorders). Just under a third (31 per 
cent) of parents would inform a minor of Alzheimer’s disease results before majority, 
with 55 per cent deferring disclosure until majority, and 14 per cent indicating that 
they would never tell their child the test results.345
United States geneticists and primary care physicians were also asked whether an at-risk 
sixteen-year-old should be allowed to refuse genetic testing, if his parents wanted him 
tested for a condition which was preventable or treatable if diagnosed early; a condition 
for which there was no effective prevention or treatment; or a late-onset condition.346 
Paediatricians were more likely than other specialists to say that a sixteen-year-old 
should not be able to refuse testing for a treatable disorder. However, geneticists too 
were generally against sixteen-year-olds being able to refuse testing for a preventable 
or treatable disorder (just 22 per cent indicated that they should be able to refuse). 
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Almost all of the geneticists believed that a sixteen-year-old should be able to refuse a 
genetic test for a late-onset disorder (95 per cent), or a disorder for which there was no 
effective prevention or treatment (96 per cent). Fewer of the primary care physicians 
believed that sixteen-year-olds should be able to refuse testing for a condition for 
which there was no effective prevention or treatment (84 per cent), and fewer still 
believed that they should be entitled to refuse testing for a late-onset condition (68 
per cent).347 
Wertz comments that America’s ‘overwhelming cultural belief ’ in autonomy is 
reflected in the survey responses. For example, more than a third (36 per cent) of 
United States geneticists thought that patients were entitled to whatever services for 
which they could pay out of pocket, compared to just 4 per cent of United Kingdom 
geneticists. Wertz notes that ‘Many US physicians appear to have forgotten that they 
can ethically refuse a service that provides no known medical benefit’.348 However, 






.  europe: euroscreen survey of eshg geneticists, 
A subgroup of the EUROSCREEN Project (set up by the EU to examine bioethical 
issues) distributed questionnaires to 932 ESHG members regarding their attitudes 
about genetic testing of children. The response rate was low: 189, or 20 per cent. 
Respondents were questioned as to their willingness to test a child in each of ten 
distinctive scenarios, relating to carrier or predictive testing for various disorders, at 
various ages, and in various family circumstances.350
Respondents exhibited a general reluctance to undertake predictive genetic testing of 
young children, more so in relation to testing for HD than for a BRCA1 mutation:
162/189	(86	per	cent)	were	unwilling	to	test	a	2-year-old	and	161/189	(85	per	






There was less reluctance among European geneticists to test for carrier status for 
cystic fibrosis (CF), particularly where the child to be tested was old enough to 





By their answers, most of the respondents indicated that their decisions would be 
modified by the expressed preferences of a twelve-year-old child.353 
Because of the low response rate the researchers did not attempt to search for 
statistically significant differences between countries: the respondents could not be 
regarded as representative of their nations.354 However, there were more responses 
from Britain (twenty-five) and from Germany (thirty) than from other countries, 
and so these were compared with each other, and against the overall patterns of 
‘willingness’ to test. British geneticists were somewhat less willing to test children 
than the overall set of respondents, and German geneticists were markedly less 
willing to test children.355 
Some respondents from Turkey, Japan, the former USSR, Britain, Denmark, Greece, 
Italy and Spain indicated that they were very willing to test children for a variety of 
disorders, including HD or CF carrier status. There was much greater consensus to 
defer testing among the respondents from Scandinavia, the Netherlands, Germany 
and Austria.356 
.  united kingdom: cgs report
The Report of a Working Party surveyed geneticists, co-workers, paediatricians, 
haematologists and family and patient support groups.357
Two-thirds, or 184, of the 512 respondents (66 per cent) considered predictive genetic 
testing in childhood to be justified in some circumstances where there might be a 
health benefit to the minor (e.g. by way of monitoring diet, treatment surveillance 
or other improvement in medical management). Sixteen per cent of respondents 
considered that such testing was not justified. A minority of respondents indicated 
that they wished to offer testing for disorders for which there were no clearly 
established beneficial interventions. 
There was also a myriad of views on the rights of parents to request genetic testing 
for their child even when the result would have no direct health benefit for the child. 
Geneticists (57 per cent) and particularly their co-workers (29 per cent) were less 
likely than paediatricians (75 per cent) to consider parental wishes alone sufficient to 
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justify testing children. Eighteen (39 per cent) of the clinical geneticists thought that 
a parental right to request should apply to testing for certain disorders only. However, 
the majority of respondents (364=71 per cent), and paediatricians and haematologists 
in particular, thought that parents did have the right to request predictive or carrier 
testing for their child. Similarly, 74 per cent of the respondents agreed that it was up 
to the family to decide (not only to request) whether or not their children should 
undergo predictive or carrier testing: geneticists 46 per cent; co-workers 35 per cent; 
paediatricians 79 per cent; and haematologists 84 per cent. 
In terms of which people or agencies had the right to request genetic testing of a 
child, the predominant view amongst geneticists and their co-workers was that they 
would not consider requests from anyone other than the parents or their medical 
advisers. Paediatricians were more willing to accept requests for genetic testing from 
adoption agencies. Haematologists thought that medical practitioners should have 
the right to request testing.
Apropos attitudes about purported advantages and disadvantages of genetic testing 
in childhood:
There	was	some	evidence	that	respondents	were	more	confident	of	recognizing	
potential	 advantages	 of	 testing	 than	 they	 were	 of	 recognizing	 the	 potential	
disadvantages.358
The seven points offered as potential advantages of genetic testing in childhood 
were all regarded positively by a large majority of the respondents. However, 
clinical geneticists were less likely to agree and all fieldworkers disagreed with the 
statement that testing in childhood would result in a ‘more responsible’ approach to 
reproductive matters in later life. A majority of paediatricians and others agreed with 
that statement. 
In terms of attitudes about the potential disadvantages of genetic testing in childhood, 
professional differences were noted. 
Paediatricians	were	evenly	divided	as	to	whether	or	not	the	child’s	sense	of	self-
esteem	 could	 be	 damaged	 by	 testing,	 whereas	 a	 small	 majority	 of	 geneticists	
and	 a	 large	 majority	 of	 fieldworkers	 thought	 that	 this	 could	 be	 an	 important	
disadvantage	of	such	testing.359	
Some months after the first questionnaire, a supplementary questionnaire was sent to 
members of the CGS and to consultant members of the British Paediatric Association. 
The second questionnaire asked whether respondents would be willing to arrange 
predictive or carrier testing of a five-year-old for a number of different disorders. ‘It 
was hoped that differences in the acceptability of testing for different disorders might 
allow inferences to be drawn about the factors that influence professional attitudes’.360 
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There was a total of 324 responses: 260 paediatricians; forty-nine geneticists; seven 
co-workers; and eight haematologists. The same trends emerged as from the earlier 
questionnaire: paediatricians were more likely than geneticists and co-workers to 







Only in respect of HD and prion-protein dementia was there widespread unwillingness 
to carry out predictive testing of a young child. However, many paediatricians still 
expressed a readiness to carry out predictive testing of a five-year-old for these 
disorders. There was a lack of consensus over testing for other late-onset disorders 
for which there were no useful interventions. 
A letter and a set of questions were sent to 108 family support groups affiliated to 
the GIG. The Working Party hoped to arouse interest in the issues and elicit accounts 
of family experiences of childhood testing, and to discover the attitudes of those 
affected by genetic disorders and their families.362
They received seventy-eight replies, which were grouped into three broad categories. 
There were forty-one replies that favoured a policy of not performing predictive 
testing or carrier testing in children. Reasons given for opposition to such testing 
included the belief that testing destroys the innocence of childhood; testing should 
not be done for parental peace of mind; the decision is for the child in adulthood; 
testing might label children; and society might become less tolerant. Those opposed 
to predictive or carrier testing of minors generally favoured the right of health 
professionals to decide whether or not to proceed with parental requests for testing. 
There were fourteen replies that indicated that carrier testing in childhood was 
appropriate, but predictive genetic testing was not. Some of these had reservations 
e.g. that the child had the right to decide about testing at an age-appropriate time. 
A further nineteen replies indicated support for predictive genetic testing, and were 
roughly evenly divided as to whether carrier testing was appropriate.363 Those who 
supported genetic testing in childhood gave reasons such as that parents should have 
the opportunity to either allay their fears and the stress on the family, or to make 
provision for the moral, emotional and financial support of their child; the person 
‘at risk’ for late-onset disorder should be made aware of it in order to prepare for the 
future; and carrier testing is essential so an informed decision on reproduction can 
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be made. Those in favour of childhood testing were generally opposed to professional 
control of testing, viewing it as overly paternalistic. 
.  women’s institute members and first-year social science students
Richards et al. sent a postal survey to Women’s Institute (WI) members who 
participated in the Women’s Institute-organised Conference on New Genetics in 
1995. Each of the sixty-four attendees was also asked to pass on questionnaires to two 
other members of their local WI who were of similar age and had a similar number of 
children (which yielded a further 128 respondents). A similar questionnaire was also 
completed by seventy-three first-year university social science students.365
The questionnaire posited a number of statements and asked the respondents to 
indicate to what extent they agreed with the statements. In response to the statement 
‘Parents have a right to ask for their child to be tested for genetic disorders that 
develop in adulthood’, respondents were fairly evenly divided, with the students 
showing slightly more disagreement. A bare majority of middle-aged women and 
slightly fewer students believed that parents should have a right to have their children 
tested for late-onset disorders.366
Only a minority of respondents (19 per cent of students, and around 25 per cent of the 
WI members) indicated that they were themselves interested in having a predictive 
test for a late-onset disorder. However, as Richards notes: ‘Of course, it is quite 
consistent to believe that such a right should be generally available but not choose to 
exercise that right in the case of your own family of yourself ’.367 However, he cautions 
that the respondents may not have been fully aware of the implications of predictive 
testing of children and that they perhaps saw the issue ‘as more of a general one about 
the position of parents in relation to their children than a balancing of the pros and 
cons of genetic testing from both the parents’ and the child’s perspective’.368
.7  FaP patients’ attitudes to predictive testing of children
Sixty-two adults affected by the FAP mutation were questioned by Whitelaw et al. 
(1996) in semi-structured interviews as to their views on the most suitable age to 
test children for the FAP mutation, and to inform them about FAP. The vast majority 
(fifty-eight, or 93.5 per cent) indicated that they would like their children tested at 
birth, if this were possible. One participant indicated that testing at ten years of age 
was appropriate, and the remaining three indicated that testing should be undertaken 
at puberty.370 Reasons given by those who wished for their children to be tested for 
the FAP mutation at birth, included removing the ambiguity about the disease status 
of their children and satisfying parental curiosity.371 
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In terms of the most suitable age at which to inform children about FAP, twenty of 
the fifty-one participants who responded to the question indicated that ten years of 
age was appropriate. A further thirteen suggested between the ages of thirteen and 
fourteen years was the most suitable age. Just three respondents thought that a child 
should be informed below the age of ten years, and one thought that the information 
should be deferred until the child was over fourteen years. The remainder indicated 






per	 cent)	wished	 to	 test	 their	 children	at	birth	and	withhold	 this	 information	
from	them	for	a	decade.373
.  united states: laboratory polices and practices (7)7
Around a quarter (26 per cent) of Wertz and Reilly’s 105 laboratory respondents 
thought that ‘parents should always have a right to request tests on behalf of their 
minor (less than eighteen years old) children, even if the child objects’. Assuming 
that the child does not object, 61 per cent of respondents indicated that they would 
process a sample for carrier testing for CF where parents have requested it for a 
seven-year-old.375
The age of sixteen appeared to be the pivotal point at which many respondents thought 
‘adolescents should be able to request tests on their own’. Half considered sixteen or 
seventeen to be the appropriate age, 27 per cent favoured the ages of fourteen to 
fifteen, and 15 per cent thought that minors should not be able to request tests until 
they reached the age of majority. The vast majority of the laboratories reported that 
they would test a sixteen-year-old for carrier status if the adolescent requested it.376 
A total of 18 per cent of laboratories had been called by physicians who had expressed 
concern about the ethics of testing children or adolescents (concerns were spread 
equally across the minors’ ages).377
.  Paediatric residents7 
A questionnaire designed by Rosen, Wallenstein and McGovern to determine 
attitudes towards genetic testing of minors was distributed to 160 paediatric residents 
in training programmes at three metropolitan New York hospitals. A total of sixty-
four residents responded, giving a response rate of 40 per cent. 
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The questionnaire was based on two clinical vignettes. One involved a four-year-
old boy with fragile X retardation. Questions related to the duty of the physician to 
inform other family members of the diagnosis; the duty to inform the parents about 
the possibility of prenatal testing (PNT); and the appropriateness of carrier testing a 
cognitively normal nine-year-old sister. The second vignette related to a ten-year-old 
boy at risk for HD. Questions related to the minor’s autonomy; informed assent; and 
the importance of certain factors in deciding whether and when to order a test for 
the minor.
4.9.1  Vignette one: Four-year-old boy with fragile X
The vast majority of respondents recognised a responsibility to inform the mother 
of such a child of the availability of PNT. Most (84 per cent) would also suggest that 
the mother inform her wider family of the diagnosis, and 70 per cent indicated that 
they would follow up to ensure that this had occurred. The vast majority (89 per 
cent) recognised the need to inform the boy’s sister of the heritable pattern of the 
disorder: 31 per cent indicating it would be appropriate to do so at the girl’s current 
age of nine, and 86 per cent indicating it would be appropriate to do so by the time 
she reached her teenage years. Eighty-five percent also recognised the need for carrier 
assessment of the daughter, with 56 per cent indicating willingness to order carrier 
testing at the girl’s current age of nine.
4.9.2  Vignette two: Ten-year-old child at risk for HD
Thirty-nine per cent of the respondents indicated that they would test the ten-year-
old for HD if the parents requested it, while 45 per cent would not, and 16 per cent 
were unsure. Of the respondents who indicated that they would test at the age of ten 
years, approximately a quarter (24 per cent) said that they would obtain assent from 







The lack of any preventive measures or treatment (39 per cent) and parental 
reaction if the results were positive (33 per cent) were the main reasons given 
by those who would not order a predictive HD test for the ten-year-old. 
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.0  Paediatricians’ and geneticists’ attitudes regarding predictive testing of   
 minors0
The authors, Campbell and Ross, conducted semi-structured interviews with a 
convenience sample of thirteen geneticists and twelve paediatricians regarding how 
they would react to parental requests for predictive genetic testing of their children, 
and their attitudes about testing their own children. The interviews explored issues 
relating to access and confidentiality with regard to genetic testing of children for 
conditions such as PKU (genetic disorder characterised by inability to utilise the 
essential amino acid phenylalanine),381 Duchenne muscular dystrophy (DMD), 
familial adenomatous polyposis (FAP), BRCA1 mutations, ApoE mutations 
(associated with late-onset dementia),382 carrier status for autosomal recessive 
conditions and behavioural genetics.383 
Differences between paediatricians and geneticists were not significant, perhaps 
due to the small sample size. All of the health professionals were in favour of PKU 
testing. However, there were differing views regarding the appropriateness of testing 
for early-onset conditions for which early treatments were ineffective. Similarly, there 
was divided opinion about testing adolescents for the BRCA1 mutation or for carrier 
status. The health professionals were generally opposed to testing for behavioural 
genetics and for late-onset conditions for which no treatment exists (e.g. for the 
ApoE mutation). Overall, 72 per cent of the participants disagreed with the use of at 
least one of the genetic tests in children or adolescents.384
Despite the willingness of some health professionals to perform predictive testing of 
children for early-onset conditions for which no effective interventions exist, two-
thirds indicated that they would not want to pre-symptomatically test their own 
children if they were at risk. They were also less likely to test their own children for 
BRCA1 or carrier status. 
However,	if	their	own	adolescent	requested	testing,	and	there	was	a	family	history,	
virtually	 all	 of	 the	 HCPs	 would	 support	 their	 adolescent’s	 request	 for	 BRCA	
testing	and	a	majority	would	support	their	adolescent’s	request	to	learn	his	or	her	
carrier	status	and	ApoE4	status.	Behavioural	conditions	were	the	only	conditions	
for	 which	 less	 than	 50	 per	 cent	 of	 the	 HCPs	 would	 support	 their	 adolescent’s	
request	for	genetic	testing.385	
None of the health professionals would test adolescents for any of the conditions 
under discussion solely on the basis of a parent’s consent: all of them would require the 
adolescent to be part of the consent process. Additionally, some health professionals 
would allow the adolescent to consent on his/her own to BRCA 1 testing (16 per 
cent), to carrier testing (24 per cent) and to ApoE4 testing (4 per cent).386
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The majority indicated that they would allow parents to test an infant child for BRCA 
1 (80 per cent) and carrier status (72 per cent). Only a minority would allow parents 
the same right in respect of testing an infant for the ApoE4 mutation (32 per cent) or 
for behavioural conditions (36 per cent).387 
The results indicated that hesitancy to provide genetic testing when it was not 
clinically indicated increased as the time between testing and disease-onset increased, 
and when the testing was less accurate or specific (e.g. for ApoE4 and behavioural 
genetics).388 
Overall, health professionals were often willing to comply with parental requests 
for genetic tests that they did not believe were clinically useful and would not 
procure regarding their own children, even if they were at risk. However, most of 
the participants (72 per cent) would refuse to provide at least one of the genetic tests 
under discussion.389 
.  medical students’ attitudes0 
A survey was distributed by Riordan and Loescher to all 428 University of Arizona 
medical students during the 2003–4 year. The survey consisted of three vignettes 
regarding genetic testing for HD, for the BRCA 1 mutation and carrier testing for 
CF. For each vignette students responded to whether they would provide testing for a 
seven-year-old and a seventeen-year-old, and their reasons in respect of each age and 
each condition. The response rate was 31.5 per cent (n=135).391
Medical students were significantly more likely to test a seven-year-old for CF carrier 
status (57 per cent) than they were for a BRCA 1 mutation (47 per cent), or an HD 
mutation (40 per cent). Students were significantly more likely to test a seventeen-
year-old than a seven-year-old, for all of the conditions: 84 per cent would test a 
seventeen-year-old for CF carrier status, 83 per cent for a BRCA1 mutation, and 77 
per cent for HD. When the ‘yes’ and ‘maybe’ responses were combined, a majority of 
students would agree to or would consider testing a seven-year-old or a seventeen-
year-old for all of the conditions.392 
Students who had completed a medical genetics course were less likely to test either 
age group for any of the conditions, than students who had not completed a formal 
genetics course. However, the only statistically significant difference was that those 
who had completed a genetics course were less likely to test a seven-year-old for a 
BRCA 1 mutation (26 per cent), than students who had not completed a formal 
course (62 per cent).393 
The main reasons students gave for not providing genetic testing were autonomy 
of the minor; no medical benefit to testing; possible psychosocial harm; limited 
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predictive value of test; insurance; and the legal status of the minor. Concerns about 
the minor’s autonomy and a lack of medical benefit were the main reasons medical 
students would refuse testing of a seven-year-old for any of the conditions. Possible 
psychosocial harms arising from testing were particularly a concern in respect of 
testing a seven-year-old. The limited predictive value of a BRCA1 test was a reason 
cited to not test a seven-year-old or a seventeen-year-old.394
The main reasons students gave in favour of testing were categorised as being early 
detection/preventive measures; mature minor; minor personally requests testing; 
ability to prepare for future, and make reproductive choices; possible future treatment; 
parental autonomy; right to know; no harm caused by testing; and important to 








measures	 for	 breast	 cancer.	 Many	 students	 identified	 possible	 treatment	 as	 a	
reason	to	test	a	7-	and	a	17-year-old	for	CF	carrier	status.395	
Several of the medical students indicated that they would require the seventeen-year-
old to undergo counselling or would need to evaluate each case individually prior to 
deciding whether or not to test.396
.2  attitudes of mothers of paediatric oncology patients towards cancer   
 susceptibility testing7
Patenaude et al conducted interviews with forty-seven mothers of paediatric oncology 
patients about their interest in hypothetical predisposition testing for themselves and 
their healthy children, and the anticipated impact of testing.398
If genetic cancer predisposition tests were available, 51 per cent of mothers would 
test themselves and 42 per cent would test healthy children even when there was no 
medical benefit to testing. If there were medical benefits to testing, then an additional 
36 per cent of mothers would seek testing for themselves, and another 49 per cent 
would seek testing for their healthy children.399 
Mothers who would not be tested in either case reported absence of family history, 
not wanting to live in fear, and the belief that there was nothing to be done about it, 
as reasons for not wanting testing. The few mothers who would not test their children 
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whether or not there were medical interventions available cited the following reasons 
for their position: not wanting to worry themselves or their children; wanting to 
leave the choice about testing up the child; avoiding the risk of uninsurability; and 
believing that the knowledge would not change anything.400
In terms of how they would respond to knowledge that their healthy child carried 
a mutation predisposing him or her to cancer: 64 per cent of mothers thought that 
they would become depressed; 55 per cent thought that they might seek counselling; 
and 66 per cent thought they would implement lifestyle changes, such as quitting 
smoking and improving diet. Ninety-two percent reported that they would react 
more urgently to symptoms that could indicate cancer; 85 per cent would have more 
tests performed regularly on the child; 81 per cent would increase the frequency of 
the child’s medical appointments; 74 per cent would generally watch over the child 
more carefully; 51 per cent felt that they would be more likely to give the child more 
attention; and 36 per cent said that they would be likely to seek counselling for 
the child.401
Mothers reported that knowing that the child did not carry the mutation would 
lower their anxiety about the child’s health.402
In terms of decision-making in respect of a child, 21 per cent of the mothers stated 
that parents alone should make the decision about whether to have a child tested for 
cancer susceptibility. Twenty three percent felt that children’s views should be sought 
and considered in the decision, and 55 per cent thought that the extent of the child’s 
involvement in the decision should very much depend upon the child’s age.403 
The age at which mothers felt that children could be involved in the decision-making 
was highly variable: 9 per cent would consider the views of a child under seven years; 
18 per cent would consider the wishes of a child between the ages of seven and ten 
years; half (50 per cent) would consider the views of children between the ages of 
eleven and seventeen years; while 22 per cent would only involve those over the age 
of eighteen years in the decision-making process.404 
Age was also considered to be in determining factor in when mothers thought 
children should be told the test results: 5 per cent favoured telling children under the 
age of seven years; 12 per cent would tell a child between seven and ten years; just 
over half (51 per cent) would tell a child between the ages of eleven and seventeen 
years; and a third (33 per cent) would not tell a child the test results until he or she 
was eighteen years old.405
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.  attitudes of adults tested for Brca mutation0 
Hamann et al. (2000) noted that most of the research on attitudes towards genetic 
testing of minors is ‘based on responses to hypothetical scenarios presented to 
individuals who have not experienced genetic testing’.407 Their study focused on 
attitudes towards BRCA1 testing for children among adults who had received test 
results themselves for a family-specific BRCA1 mutation. 
Two hundred and eighteen individuals were followed up by telephone interview four 
to seven months after receiving their BRCA1 tests results. Only 26.1 per cent agreed 
that children under the age of eighteen years should have the opportunity to be tested 
for a BRCA1 mutation. The majority (61 per cent) disagreed, and a further 9.6 per 
cent responded that they did not know or that ‘it depends’.408
Predictors of permitting testing for children under the age of eighteen years included: 
being male, being a non-carrier, and not having a mother with breast cancer. Not 
having minor children, and having generally positive attitude about the benefits of 
genetic testing, were also associated with permitting testing.409 
Of the 218 participants, 104 had minor children. Only eighteen of these individuals 
(17.3 per cent) indicated that they would want their own children tested for a BRCA1 
mutation; 82.7 per cent would not want their children tested. Most of the participants 
were consistent in disagreeing that children under eighteen should be allowed testing, 
and that they would not want their own children tested; however, 7.7 per cent who 
permitted testing for children under eighteen years would not endorse it for their 
own children, and 4.8 per cent did not support testing of children generally, but 
wanted it for their own children.410
Hamann et al. noted that their findings, amongst people who had actually been tested 
themselves for the BRCA1 mutation, showed significantly less support for genetic 
testing of minors (e.g. compared to Patenaude’s study with mothers of paediatric 
oncology patients).




.  switzerland: Future lawyers’ and physicians’ attitudes towards predictive   
 testing for hD, 2002
Between 1994 and 1997, six groups of fifth year medical students attending the legal 
medicine and clinical ethics courses at the Universities of Geneva and Lausanne, 
and five groups of students attending law and medicine courses at the same 
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universities, participated in the Elger and Harding research programme. They all 
received an introduction to fundamental issues of medical law and ethics, including 
a presentation on informed consent, competence and confidentiality. They also 
received some information about HD and watched a fifteen-minute video interview 
of a thirty-eight year old woman who had recently been diagnosed as suffering from 
HD. The video informs the viewers that the woman has two sons aged ten and sixteen 
years and she is adamant that she does not want them told about or tested for HD at 
the moment.
Students filled out a standard questionnaire as to their level of agreement with 
statements regarding whether the older son should be informed of his mother’s HD, 
and whether the children should be tested for HD.
The global response rate was 86 per cent. No differences were found between medical 
and law students with regard to their answers about the adolescent son: 75 per cent 
thought that the sixteen-year-old son should be informed of his mother’s HD, despite 
her wishes; and 91 per cent indicated that he should have the chance to be undergo 
predictive testing for HD if he wanted to. However, significant differences were found 
regarding testing the ten-year-old son: more law students (44 per cent) than medical 
students (30 per cent) were in favour of testing the younger son for HD against his 
mother’s wishes.413 
Most of the comments in respect of whether or not the sixteen-year-old son should 
be informed of the mother’s HD were to qualify agreement with the statement. 
For example, ‘the question needs to be discussed with parents’, and ‘inform if the 
adolescent is sufficiently mature’. Some students, particularly medical students, 
were concerned about the psychosocial harm that might result from informing the 
adolescent.414
Those opposed to informing the adolescent raised related concerns: it is the parents’ 
decision to inform; the adolescent is not mature enough to be informed; and 
psychosocial harms might result from informing him.415 
With regard to whether the sixteen-year-old should have the chance be tested for HD, 
many students emphasised the importance of the testing being voluntary, and not an 
obligation. The very few students who opposed allowing the sixteen-year-old to be 
tested indicated that he was ‘too young’. 416 
Several students felt that the ten-year-old was too young to understand the 
implications of HD testing, and that testing should be deferred. Some who agreed 
that he should be tested advocated testing but not informing the child of the results. 
Concerns were expressed about the potential psychological harm that could result in 
informing or testing the ten-year-old.417
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The authors note that their study differed from others in that they questioned 
participants as to whether minors should be tested against	parents’ wishes. 
Clearly,	students	thought	that	parents’	desire	that	their	child	not	be	tested	should	





Elger and Harding suggest that the potential benefits of knowing one is at risk for 
HD, or of being tested, may not have mentioned by many students because of the 
extreme distress of the woman whom the students watched on the video. However, 
they also highlight that the ‘rather negative risk–benefit ratio was not a sufficient 
reason for most students to override the right of the adolescent to be tested’.419
They raise the idea that the youthfulness of the survey participants might have 
influenced their reluctance to say that adolescents should not have choices in respect 
of testing, having recently been that age themselves.420





.  Belgium: Flanders midwives’ and nurses’ attitudes towards predictive testing  
 for breast cancer and hD22
Postal questionnaires were sent by Welkenhuysen and Evers-Kiebooms (2003) to 
119 midwives and 881 nurses, with a response rate of 58 per cent (n=69) from the 
midwives, and 33 per cent (n=293) from the nurses. Among other questions relating 
to predictive testing of adults, respondents were asked to indicate their level of 
agreement with the acceptability of predictive testing for BRCA1 or HD in the case 
of parents requesting a test for their five-year-old child, and in the case of a sixteen-
year-old adolescent requesting testing for herself. They were also asked to explain 
why they agreed or disagreed with such testing.
There were no significant differences between the midwives’ and the nurses’ responses. 
Agreement was highest for an adolescent requesting a predictive test for BRCA1, with 
88.4 per cent agreeing at least somewhat to completely. A total of 82.3 per cent agreed 
at least somewhat to completely with adolescents requesting a predictive test for HD. 
The next highest level of agreement was for parents requesting a predictive test for 
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HD for a five-year-old, with 54.4 per cent agreeing at least somewhat to completely. 
And, finally, just 43.1 per cent agreed somewhat to completely about the acceptability 
of parents requesting a BRCA 1 test for a five-year-old.423 
In terms of reasons given for the level of agreement or disagreement with testing of 
minors:
Ethical	 arguments	 referring	 to	 personal	 autonomy	 were	 mentioned	 frequently	
for	 all	 four	 ratings	 concerning	 minors:	 in	 the	 case	 of	 testing	 an	 adolescent	 at	
his/her	own	request	(table	8),	 they	concerned	the	autonomy	of	the	adolescents	
and	were	used	as	arguments	 in	 favour	of	 testing;	 in	 the	case	of	 testing	a	child	
at	the	parents’	request	(table	7),	they	concerned	the	autonomy	of	the	child	and	
were	used	as	arguments	against	testing.	On	the	other	hand,	a	minority	tended	




to	 psychological	 issues,	 they	 were	 more	 prominently	 used	 (see	 tables	 7	 and	 8)	
as	arguments	against	predictive	testing	of	minors	than	as	arguments	in	favour,	
with	 special	 attention	 for	 psychological	 ‘immaturity’	 as	 an	 argument	 against	
predictive	testing	in	adolescents	at	their	own	request.424
The authors note in their discussion that the ethical arguments in favour of testing of 
adolescents at their own requests ‘are in line with the general evolution in medicine 
not to adhere to a strictly age-based criterion, but to take into account the adolescent’s 
maturity and decision-making competence’.425 
.  the netherlands: Parental attitudes towards testing for familial    
 hypercholesterolaemia (Fh)2
This paper by Umans-Eckenhausen et al. (2002) reports on a telephone survey with 
seventy parents in thirty-five different FH kindreds. Half of the participants were FH 
carriers, and the other half were their spouses. Sixty-one (87 per cent) of the parents 
wanted their children tested for FH, while nine parents (13 per cent) did not. The 
parents were unanimous in twenty-eight of the thirty-five couples (twenty-seven in 
favour of testing, one couple against), and in seven cases the parents disagreed.427
Whilst parents indicated that ‘information’ was the most important factor in their 
decision-making about testing, the multivariate analysis showed that emotion 
was the actual only predictive factor of the decision to test. ‘These data indicate 
that the decision is based less on rationality than parents wish to believe.’428 
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.7  china: geneticists’ views of predictive testing of minors for late-onset   
 disorders2
Postal questionnaires were sent by Mao to 402 Chinese geneticists, eliciting their 
views on a wide range of ethical issues involved in genetic testing and screening. A 
total of 255 (63 per cent) geneticists responded. 
The geneticists were questioned as to whether parents should be able to have their 
children tested for late-onset conditions or predisposition to such conditions. 
The results were: 85 per cent indicated that children should be tested for HD, and 
susceptibility to cancers upon parental request; 84 per cent thought that children 
should be tested for familial hypercholesterolemia; 69 per cent considered that they 
should be tested for predisposition to alcoholism; and 61 per cent indicated that 
parents should be able to have their children tested for predisposition to Alzheimer’s 
disease.430 
Most geneticists favoured such testing on the basis that parents should be able to 




is	often	 seen	as	part	of	a	collectivity	(the	 family),	 rather	 than	as	a	potentially	
autonomous	individual.431	
.  high school screening programmes
We briefly present some attitudes regarding participation in high school screening 
programmes because minors’ attitudes in respect of genetic testing can get lost 
amongst the louder and more powerful voices of the other parties involved in such 
decisions (various health professionals and parents). 
4.18.1  Tay-Sachs disease screening in Jewish schools in Melbourne, 2003432
The two most relevant reasons given by the 474 students who chose to undergo testing 
as part of the TSD screening programme were a desire to know their carrier status, 
and testing for the purpose of future reproductive decision-making. Other reasons 
given included: testing was promoted as a good thing do by the Jewish community; 
the appeal of being tested now and make up one’s mind about getting the results later 
in life; and it being easier to have the test now rather than later.433
Reasons given by the 236 students who opted not be tested as part of the screening 
problem included: not wanting to know about carrier status at this point in life; an 
aversion to needles; believing that one’s risk was low for being a carrier; parents’ 
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refusal; the cost of the test; the fact that parents had been tested and were not carriers; 
and never wanting to know if one was a carrier.434
The authors note that a significant proportion of the students who refused testing, 
did so because of a fear of needles (47 per cent). Forty-four of the students who 
declined testing were asked whether they would be tested if a cheek brush test was 
offered as an alternative to a blood test; eighteen (41 per cent) indicated that they 
would agree to be tested in those circumstances.435 
4.18.2  Attitudes of school community towards susceptibility screening for    
 haemochromatosis436
Nineteen schools in urban and rural Victoria were approached to participate in a 
survey seeking to establish the Australian secondary school community’s attitudes 
towards genetic susceptibility screening in schools, with hereditary haemochromatosis 
(HH) as the model condition with an available prevention. Eleven schools (58 per 
cent) agreed to participate. Researchers questioned students in their penultimate year 
of study (aged fifteen to eighteen years); students’ parents; staff associated with the 
students; and government representatives and policy-makers for health education.437 
Attitudes among the participants as a whole were positive towards genetic testing 
in schools, and even more positive towards genetic testing generally. Students were 
significantly more positive about testing after education than before, and were 
significantly more positive about testing after education, than their parents.438
Both parents and staff indicated that they would like students to be offered a 
susceptibility test for HH. The most common reasons offered in favour were: early 
detection and better management of the condition; and giving students an opportunity 
to gain knowledge about themselves. Of the parents and staff who did not want the 
students tested, 46.5 per cent indicated that they did not know enough.439
After education, 68 per cent of students, 61.4 per cent of parents, and 61.8 per cent 
of staff indicated that they would either probably or definitely have a test for genetic 
susceptibility to HH.440 The majority of both parents and staff suggested that year 
eleven (average age: sixteen years) was the minimum year level that should be offered 
such a screening programme, while students indicated that year ten (average age: 
fifteen years) was the minimum acceptable year level. 441 
The interviews with the key informants in health and education policy development 
revealed a generally positive attitude towards the concept of HH screening in schools, 
subject to conditions.442 
Gason et al. concluded that education and knowledge were major contributors to 
attitudes about genetic testing.443 

Professional practice in respect of genetic testing of minors
.  international: Predictive genetic testing of young people for non-medical   
 reasons
The survey undertaken by Duncan et al. provides the most recent evidence of 
professional practice in relation to genetic testing of minors. It is also one of the 
most geographically broad surveys. 
Duncan et al. surveyed 301 respondents from the United States, Canada, the United 
Kingdom, Australia and New Zealand who were professionally involved in predictive 
genetic testing. The vast majority (254 or 84.4 per cent) were clinical geneticists.445 
They were questioned (via an online questionnaire) as to their involvement and 
attitudes in relation to predictive genetic testing of pre-symptomatic children for 
untreatable conditions; and their views on the existing guidelines on the predictive 
testing of children.
Thirty-six clinicians (12 per cent) had been involved in providing predictive genetic 
tests to young people for non-medical reasons. There were forty-nine cases of such 
testing, in relation to fourteen different conditions. ‘This is the largest and most 
descriptive collection of such case-studies.’446
Twenty-two of the forty-nine cases (45 per cent) in which testing was provided 
involved ‘immature’ young people (under the age of fourteen years), and the 
remaining twenty-seven cases (55 per cent) involved ‘mature’ minors (fourteen years 
and older).
4.19.1  ‘Immature’ young people (under fourteen years)
Of the twenty-two cases of testing immature young people, four were prenatal tests. 
One test was provided to a young person between the ages of ten and fourteen, and 
the remaining seventeen were performed on children under the age of ten years. 
The most common conditions tested for were HD and myotonic dystrophy (four 
cases each).447 In eighteen of these twenty-two cases (82 per cent) the parents of the 
child had requested testing, and the respondents did not indicate who had requested 
the testing in the remaining four cases. Only two of the ‘immature’ young people 
tested had been informed of their test results. Those two children were nine and ten 
years old and had both received gene-negative results respectively for spinocerebellar 
ataxia and fascio scapulo humeral dystrophy.448 
The most common reason expressed for providing these tests to ‘immature’ young 
people was that parents wanted to know: ten clinicians (45 per cent) cited this as a 
reason. A further three clinicians (14 per cent) indicated that the opportunity for 
planning was a reason in their providing the test to the child. The test was conducted 
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prenatally in four of the remaining cases (18 per cent), and there were other or no 
responses regarding the remaining five tests (23 per cent).449 
Of the twenty-two cases reported, eleven (50 per cent) had been followed up, whether 
by a single telephone call, regular contact for six months or by other means. Follow-
up was undertaken by a range of professionals including geneticists, counsellors and 
psychologists. There were no reports of adverse events for the young person tested, 
although only two were reported as having been informed of their test results. There 
were, however, three cases of adverse events for parents of the minors tested: two cases 
involved parents who elected to continue pregnancy despite prenatal testing revealing 
the foetus was at increased risk for HD; and another case involved the parents of an 
eight-year-old child found to be at increased risk for Dystonia. The parents were 
distressed by the information in all three cases and were anxious about how and 
when to tell their child. There was also one beneficial effect of testing reported: 
parents were relieved and the child seemed to have forgotten about the test.450 
4.19.2  ‘Mature’ young people (fourteen years plus)
Of the twenty-seven cases of testing mature young people, the majority (eighteen) 
involved minors aged sixteen to seventeen years. Nine tests were provided to minors 
aged fourteen and fifteen years. 
The most common condition tested for was HD (fourteen cases). Other conditions 
tested for included myotonic dystrophy, breast cancer predisposition and 
spinocerebellar ataxia. In four cases (15 per cent) the young person’s parents requested 
the testing, and in ten cases (37 per cent) the young person requested testing. In the 
remaining thirteen cases (48 per cent) the request for testing came from both the 
young person and their parents. Results were disclosed to all of the mature young 
people, except for one intellectually disabled fourteen-year-old. 
The most common reason articulated for providing these tests was to resolve 
uncertainty for the young person: thirteen respondents (48 per cent) cited this as 
a reason. Seven of these requests were made by the young person alone, and six by 
the young person with his or her parents. A further six respondents (21 per cent) 
indicated that the opportunity for planning was a reason for their providing the test to 
the minor. Three of these requests were made by the young person together with his or 
her parents, two were made by the parents alone, and one by the young person alone. 
Two clinicians (7 per cent) provided tests (on parental request) because of parental 
anxiety. A further two (7 per cent) provided the tests for reproductive reasons.
Two-thirds (18/27) of the cases of mature young people who had been tested were 
followed up, in a variety of ways. Two adverse events were reported: one seventeen-
year-old male found to be at increased risk for HD was initially depressed and 
00
rebellious, but eventually accepted the result; and one seventeen-year-old female who 
was free of the HD mutation felt ‘worry and responsibility for affected mother and 
untested brothers’.451
There were also nine reported beneficial effects: six following decreased risk results 
(‘enabled him to focus on school’, ‘negative result really helped to stabilise life’ etc.); 
and three following increased risk results.452
4.19.3  Refusals to provide testing
More than half of the respondents (53 per cent, or 159) had refused to perform a 
predictive genetic test for non-medical reasons. Together these refusals were made on 
more than 800 separate occasions.453 
.20  united kingdom: cgs research
The Working Party of the CGS wrote to thirty-five molecular genetic and twenty-
three cytogenetic laboratories engaged in clinical diagnostic work, and requested 
information about the number and nature of tests carried out on children, and 
whether requests had been denied on ethical grounds.454
Replies were received from sixteen molecular genetic laboratories, of which half 
were not involved in testing that the CGS would consider ‘potentially problematical.’ 
However, six of the laboratories regularly tested young children for carrier status 
for disorders such as cystic fibrosis or sex-linked muscular dystrophy. Two of the 
laboratories specifically stated that they had a policy not to perform predictive or 
carrier tests on children.455 
Ten of the twenty-three cytogenetic laboratories provided details about their testing 
of children: most tested samples from several children each year to determine whether 
they carried hereditary chromosomal rearrangements.456 
The Working Party also undertook a questionnaire survey with approximately 3000 
health professionals in Britain, seeking information about practice and attitudes in 
relation to the genetic testing of children.457 The research confirmed that genetic 
testing of children was ubiquitous, although most testing fell outside the Working 
Party’s remit (that is, it involved testing for early onset disorders or for conditions for 
which medical interventions or surveillance could be of some timely benefit).458 
Slightly more than a third (184 or 36 per cent) of the 512 respondents had 
received requests for predictive testing in respect of 902 children. Many of the tests 
performed were for conditions with childhood onset or for which there were medical 
interventions available. Many requests for predictive testing were declined or deferred, 
particularly for neurodegenerative disorders, but also for retinitis pigmentosa, 
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polycystic kideney disease and FAP. Some requests for predictive testing for myotonic 
dystrophy, polycystic kidney disease and hypertrophic obstructive cardiomyopathy 
were accepted and carried out.
A greater proportion of respondents (41 per cent) had received requests for carrier 
testing of minors. Many of these tests were carried out in respect of disorders 
such as familial chromosomal rearrangements, Duchenne and Becker dystrophies, 
cystic fibrosis, the heamoglobinopathies, X-linked visual disorders, fragile X and 
coagulopathies. Others were declined or deferred; for example, for cystic fibrosis, 
Duchenne muscular dystrophy and chromosome translocations. Only a very small 
minority (eighty-five) had an age limit below which they would not carrier test, and 
those age limits ranged from one to eighteen years. The numbers of children on 
whom testing was performed or requested was reported as 1706 annually, although 
this figure was probably only a proportion of the tests carried out. 
The report remarked that it was certainly common paediatric practice to carrier 
test siblings of children affected with a recessive heritable disorder (e.g. cystic 
fibrosis).459
Due to the difficulty of gathering retrospective data and its potential for unreliability, 
the Working Party also undertook a twelve-month prospective study of genetic 
testing in children (under sixteen years), commencing on 1 January 1992.460
Seventeen molecular genetic laboratories supplied data, and the Working Party also 
circulated clinical geneticists, CGS members and consultant paediatricians. The 
Report cautions that the limited sampling could only yield indications of the pattern 
of childhood testing and not an accurate measure of the current activity (and the 
numbers listed were likely to be under-estimates).461
In 1992 around 165 genetic tests were performed on children, and thirty-seven were 
deferred. The most common test was for cystic fibrosis carrier status (sixty-eight 
tests, nine deferred). Around a quarter of the tests (forty-two) were predictive, most 
of which were for the FAP or myotonic dystrophy mutations, and the remainder were 
carrier tests. Two requests for predictive HD testing of a five-year-old and fourteen-
year-old were deferred. There was no evidence that tests were more commonly 
performed later in childhood; age distribution appeared to be random and not 
concentrated in early adolescence.462 
The United Kingdom CGS survey results do not indicate how many requests for 
carrier or predictive tests health professionals had received from competent minors. 
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.2  advisory committee on genetic testing and the Department of health   
 survey
A survey questionnaire asking about tests performed on children under the age of 
fourteen years in 1997–8 was sent to 2040 consultants in paediatrics, genetics and 
paediatric surgery and 144 genetic nurses and counsellors. A total of 692 completed 
responses were received. The response rates were 32 per cent for paediatricians; 66 
per cent geneticists; 28 per cent surgeons; and 18 per cent nurses and counsellors.463
One hundred and sixty-five respondents had performed tests for late-onset disorders 
on a total of 955 children. The main reason for testing was medical benefit; the main 
reason for refusing to test was the child’s right to make his or her own decisions when 
mature enough.464 
Two hundred and eighty-nine professionals had performed a total of 5543 tests for 
childhood-onset disorders. The most common tests were ordered by professionals 
who were involved with the heamoglobinopathies or cystic fibrosis. The main reason 
given for testing was medical benefit.465 
One hundred and seventy-eight respondents had tested 3319 children for carrier 
status for autosomal recessive disorders or chromosomal rearrangements. The main 
reason reported for testing was parental pressure to test; the main reason given for 
refusing to test was the loss of the child’s autonomy.466
The maturity of the child, rather than the specific age, was considered more 
important in terms of when minors could consent to testing. Ten years was the most 
cited minimum age at which children could actively be involved in the counselling 
process, and sixteen years for giving consent to predictive testing.467 
.22  comment on Professional Practice from harper, glew and harper, 
In response to a paper in the BMJ	from Dickenson468 arguing that those under the age 
of eighteen years should be able to consent to predictive genetic testing Harper et al. 










Harper et al. argue that Binedell et al.’s paper on adolescent requests for predictive 
testing470 enjoyed widespread discussion at British and European genetics meetings, 




This	 current,	 more	 individualised	 approach	 to	 requests	 from	 adolescents	
requesting	genetic	tests	is	reflected	in	the	1998	recommendations	of	the	United	
Kingdom	health	department’s	advisory	 committee	on	 genetic	 testing	 (also	not	
referred	to).	If	the	author	had	been	in	touch	more	closely	with	clinical	genetics	




Thus, it would appear that in the United Kingdom, when a request comes from a 
minor, professionals do not rule out genetic testing simply on the basis of age.
.2  united states: nance and the united states hD genetic testing group
In 1996, surveys soliciting information about several aspects of predictive testing for 
HD were sent to all sixty-five known United States HD predictive testing centres. Of 
sixty-three responding centres, none reported performing a predictive HD gene test 
on an asymptomatic juvenile. Twenty centres had been involved with a diagnostic 
test on a juvenile, including a total of forty-eight juveniles.472 
.2  laboratory polices and practices, 77
Wertz and Reilly sent survey questionnaires to 186 laboratories. They received 
replies from 156 laboratories, although only 105 laboratories provided clinical DNA 
diagnostic services (the others tested for research purposes only). The results refer 
to the responses from the 105 clinical laboratories that provided clinical genetics 
services. 
4.24.1  Policies
Almost all of the labs (92 per cent) had requisition forms that asked the age of the 
person who was being tested. Just under half (46 per cent) had policies for the testing 
of minors for late-onset conditions, although the policies varied greatly (33 per cent 
had policies for carrier testing, and 33 per cent for disorders for which a test offers no 
medical benefit within three years). Twenty-five labs reported that they did not test 
unless there was a medical benefit; eleven reported that they decided on a case-by-
0
case basis; nine reported that they did not test for HD (including five that referred to 
the guidelines of the ASHG, Institute of Medicine, HD Society of America and the 
Canadian HD Collaborative); eight reported that they tested at the parents’ request 
after counselling; and seven reported that they did not test for adult-onset disorders 
but did test for carrier status, at the parents’ request.474
The data from the labs suggested that most labs had no comprehensive policies, even 
though 55 per cent had refused to test a minor on at least one occasion – suggesting 
that many labs were concerned about the possible effects of testing.475 
4.24.2  Practice 
Later-onset	 disorders:	 The questionnaire listed thirteen later-onset disorders and 
asked whether respondents offered tests for those disorders. For twelve of the 
thirteen disorders, laboratories that offered such tests had received requests to test 
pre-symptomatic children or adolescents. For eight of the thirteen disorders, the 
majority of the laboratories that offered a test actually had tested pre-symptomatic 
children or young people.476
With the exception of those testing for HD, few laboratories reported ever having 
refused to test on the basis of a patient’s age. The majority of laboratories had tested 
healthy children under the age of twelve years for eight disorders. For ten of the 
later-onset conditions there were no reported refusals. Approximately 22 per cent 
had tested children under the age of twelve years for HD, and 19 per cent had tested 
children between the ages of twelve and fourteen years. Of those who offered such 
tests, 44 per cent had refused to test children for HD, 17 per cent had refused to test for 
familial polyposis coli and 6 per cent had refused to test for myotonic dystrophy.477 
Carrier	 testing:	 The questionnaire asked respondents whether they had ever been 
asked to test, and whether they had tested or had refused to test, children for carrier 
status for fifteen listed autosomal recessive or X-linked disorders. For eleven of the 
fifteen disorders, the majority of laboratories that offered such tests had received 
requests to carrier-test children or adolescents. For six of the fifteen disorders 
(including five that were X-linked), the majority of the laboratories that offered a 
test had tested girls under the age of twelve years for carrier status. Few laboratories 
reported ever refusing to test for carrier status on the basis of the patient’s age. There 
were no reported refusals for ten of the fifteen disorders. However, 5 per cent reported 
refusing to test for Tay-Sachs disease, fragile X syndrome and cystic fibrosis, and 16 
per cent had refused to test for Duchenne muscular dystrophy.478  
Approx 45 per cent of laboratories had also occasionally provided tests directly to 
consumers (rather than through a physician).
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.2  international perspectives of geneticists, primary care physicians and the   
 public7
Of 1084 United States geneticists surveyed by Wertz, 38 per cent had received requests 
to test minors for adult-onset disorders (the majority of which were for HD), as 
had 20 per cent of the 409 primary care physicians who participated in the research. 
Amongst the 409 primary care physicians, 31 per cent of family practitioners reported 
requests for genetic testing of minors, compared with 27 per cent of paediatricians, 
and just 2 per cent of obstetricians.480 
.2  carrier screening programmes
Carrier screening programmes for Tay-Sachs disease have been running in high 
schools in Montreal since the 1970s, and carrier screening programmes for Tay-Sachs 
disease and other disorders have also been run in Australian high schools (among 
other places) since the mid 1990s. However, as mentioned, this section focuses on 
genetic testing of ‘at risk’ individual minors; the incidence of carrier testing of minors 
via screening programmes is not the focus.481 
.27  Discussion of attitudes and professional practice regarding genetic testing of  
 minors
4.27.1  Attitudes
There is a great deal of evidence indicating that geneticists are more reluctant to 
test minors, particularly where there are no medical benefits, than are primary and 
secondary care physicians, parents and the general public. For example, Wertz’s 
study482 revealed greater consensus amongst geneticists and primary care physicians 
that minors should be tested for hyper-cholesteroleamia (which can be medically 
managed), than that they be tested for HD, or predisposition to alcoholism or 
Alzheimer’s disease. 
These	 results	 point	 to	 a	 dichotomy	 between	 geneticists	 and	 the	 rest	 of	 the	
United	States	medical	community,	whose	views	closely	paralleled	those	of	their	
patients.483
The large surveys conducted by the United Kingdom CGS Working Party also found 
that geneticists and their co-workers were less likely than paediatricians to consider 
parental wishes alone a sufficient basis upon which to perform genetic testing of a 
minor, and that paediatricians were more willing to test minors than geneticists and 
co-workers (indeed, many paediatricians were willing to test a five-year-old for HD 
and other prion-protein dementias).484 
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One notable exception in terms of parental attitudes towards genetic testing of minors 
was revealed by the research of Hamann et al. The great majority of the participants in 
their study, all of whom had themselves been tested for a BRCA 1 mutation, thought 
that children, theirs included, should not be tested for BRCA mutations.485 




Large numbers in most of the groups surveyed or interviewed indicated that minors 
from varying ages, ranging from ten years upwards, should either be told of a genetic 
risk or test result, or play some part in the decision-making regarding testing. However, 
while most geneticists (and fewer, but still most, primary care physicians) in Wertz’s 
study thought that a sixteen-year-old should be able to refuse testing for a late-onset 
disorder or for a disorder for which there was no effective treatment, the majority of 
geneticists (and a greater number of paediatricians) considered that sixteen-year-old 
minors should not be able to refuse testing for a preventable or treatable disorder.487
All of the groups (geneticists, primary and secondary care health professionals, 
students, parents, patients and members of the public) gave broadly similar reasons 
regarding the acceptability or otherwise of genetic testing of minors for non-medical 
reasons. (Although, one unique reason offered against genetic testing by minors 
themselves was a fear of needles).488 Most of the reasons accord with the points and 
issues raised in many of the professional position statements and guidelines (and 
indeed Duncan’s research revealed a great deal of professional agreement with the 
position statements and guidelines).489 Reasons offered in favour of testing of minors 
frequently included: parental desire to know; parental autonomy; opportunity for 
planning; resolve uncertainty for young people; relieve anxiety; and reproductive 
reasons. Some of the most common arguments given against testing include: 
protecting the autonomy of the minor; no medical benefit to testing; possibility of 
testing causing harm; privacy concerns; and concerns about stigmatisation.490  
Given that all groups gave similar responses in terms of reasons for and against testing 
one might wonder at the greater reluctance of geneticists to provide genetic testing of 
minors. Duncan’s research indicates that there is a great deal of agreement amongst 
geneticists with the professional guidelines and position statements in respect of 
genetic testing of minors.491 As outlined above, the most prominent professional 
position statements take a cautionary approach to genetic testing of minors, and 
advocate that testing for non-medical reasons can generally be deferred until a minor 
can make the decision. It is fair to say that, given the nature of their work, geneticists 
are probably more aware of these position statements, and the reasoning behind 
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them, than are other health professionals. This might explain in part why they are 
generally more opposed to genetic testing of minors for non-medical reasons than 
are other health professionals, although they are still willing to consider cases on 
their individual merits.492 
Wertz suggests that the fact that United Kingdom geneticists had had greater 
experience with genetic testing requests than their counterparts from other nations 
may have partly contributed to their greater reluctance to accede to parental requests 
for testing.493 By analogy, one could surmise that the greater experience of geneticists 
in general with predictive genetic testing requests in particular (perhaps more so 
than with carrier or symptomatic testing requests) may partly contribute to their 
greater reluctance to accede to parental requests for testing. 
The	 caution	 of	 the	 geneticists	 might	 well	 arise	 from	 their	 experiences	 of	 the	
difficulties	 of	dealing	with	 such	 requests,	while	most	paediatricians	will	never	
have	been	confronted	with	these	issues	(at	least	in	the	extreme	case	of	testing	for	
HD)	in	their	clinical	practice.494	
Perhaps other health-care professionals and parental or consumer groups give more 
weight to the purported psychosocial benefits than do the geneticists who might 
give greater weight to the lack of clinical benefit, and the potential for psychosocial 
harms. For example, the United Kingdom CGS Working Party research revealed that 
more geneticists and fieldworkers than paediatricians considered that genetic testing 
could damage a minor’s self-esteem.495 The geneticists surveyed by Wertz et al. were 
also more reluctant to inform minors of genetic test results in respect of late-onset 
disorders than were primary care physicians. These findings reinforce the argument 
that geneticists may place greater weight on the potential for psychosocial harm as a 
result of genetic testing of minors for non-medical reasons.496 
Many of the groups studied for their attitudes towards testing appear to be more 
willing to provide carrier testing of minors than predictive testing.497 There are fewer 
professional position statements and guidelines on carrier testing than predictive 
testing,498 but those that exist take a generally prohibitive stance towards carrier 
testing of young children, as they do towards predictive testing. However, it seems 
that in practice people have more permissive attitudes in respect of carrier testing (as 
Hogben and Boddington have argued).499 
In some countries geneticists are more willing to test children for non-medical 
reasons than in others. Wertz’s study reveals that geneticists from southern and 
eastern Europe, the near east, Latin America and Asia are more willing to test children 
for non-medical reasons. Wertz’s findings were reinforced by the research conducted 
in China by Mao.500 
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The approach of New Zealand geneticists presumably aligns more with geneticists 
from the United States, the United Kingdom, Australia and the other English-
speaking nations, given that many of our geneticists will have trained in those places, 
and the HGSA guidelines recommend against predictive testing of minors for non-
medical reasons. However, given the ethnic diversity of our population, there will of 
course be groups with different attitudes.
4.27.2  Practice
Some	 clinicians	 are	 evidently	 accepting	 non-medical	 justifications	 for	 testing,	
implying	 that	 they	believe	 there	are	benefits	other	 than	purely	medial	benefits	
associated	with	having	knowledge	of	future	health.501
There is evidence that health professionals involved in genetics, paediatrics, 
neurology, heamoglobinopathies and other areas of medicine (including general and 
family practice) are questioned about the possibility of genetic testing of minors with 
relative frequency.502 
There is also evidence that many of these health professionals, and laboratories, are 
acceding to requests, and performing genetic tests on minors. While most of the 
tests are undertaken for medical reasons (including symptomatic testing, or testing 
for disorders for which some degree of prophylaxis or pre-symptomatic medical 
procedure may be helpful), a significant number of tests have also been performed 
for non-medical reasons.503 
There is evidence that predictive genetic tests have been performed on minors 
(in the United States and the United Kingdom at the very least) for mutations 
for HD, myotonic dystrophy (the most common form of adult-onset muscular 
dystrophy), breast cancer, spinocerebellar ataxia (‘characterized by slowly progressive 
incoordination of gait and often associated with poor coordination of hands, speech, 
and eye movements’),504 hypertrophic obstructive cardiomyopathy (excessive 
thickening of the heart muscle sometimes leading to sudden death),505 FAP and 
polycystic kidney disease, among others. There is also evidence that carrier testing 
of minors is even more widespread, for cystic fibrosis, in particular, but also for 
heamoglobinopathies, X-linked disorders, chromosomal rearrangements and other 
autosomal recessive disorders.506 
Predictive genetic testing and testing for carrier status has been conducted in respect 
of minors who range in age from zero to seventeen years. Of the forty-five cases (not 
including the four cases of prenatal testing) of predictive genetic testing of minors 
reported by Duncan, eighteen (40 per cent) were tests on minors under the age of 
fourteen years, and twenty-seven (60 per cent) were tests on minors of or over the age 
of fourteen years.507 The United Kingdom CGS prospective study of genetic testing 
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of minors in 1992 revealed a seemingly random age distribution among the minors 
tested, with no concentration of testing in early adolescence.508 The United States 
laboratories surveyed by Wertz also indicated that they had performed predictive 
tests for HD on minors both under the age of twelve years (22 per cent), and between 
the ages of twelve and fourteen years (19 per cent). 
Thus genetic testing of minors who cannot give a valid consent appears to be occurring 
against the recommendations of prominent international and domestic professional 
position statements, recommendations and guidelines. (In contrast, most of the 
guidelines are more discretionary in respect of genetic testing of competent minors 
upon request.)509 
In respect of genetic testing undertaken for non-medical reasons, many professionals 
appear to be testing minors simply on the basis of parental requests and parental 
desire to know, and to help parents plan around the information (see responses given 
by clinicians in Duncan’s study).510 More worryingly, perhaps, the United Kingdom 
Advisory Committee on Genetic Testing (ACGT) found that carrier tests were being 
performed on minors because of ‘parental pressure’.511 
Genetic tests are also performed on the basis of minors’ requests in order to resolve 
uncertainty for them and to allow them to plan around the information.512
Duncan et al. note that predictive tests on minors appear to be refused more often 
than they are performed. The main reason given by the professionals surveyed by 
Duncan and the United Kingdom ACGT for refusing carrier or predictive genetic 
testing of minors was preserving the minors’ autonomy to make their own testing 
decisions when older.513
Duncan et al. comment that, despite the majority of respondents in their study 
agreeing with the existing guidelines on predictive testing of minors, only 15 per 
cent cited policy as a reason for refusing tests. This indicates that clinicians were 
making individual clinical judgments, perhaps guided by the guidelines, rather than 
simply following suggested recommendations.514 However, whilst the reasons given 
for refusing to test are variable, most of them accord with the themes in many of the 
professional position statements; for example, protecting autonomy, lack of medical 
benefit and possible harms.
Refusals to test do not necessarily mean that the family or young person is refused point 
blank and sent away; it might mean that after discussion or counselling both parties 
agree that testing is not the best option.515 The New Zealand clinical geneticist spoken 
to also intimated that families could come around to accepting that testing is not the 
most appropriate course of action, rather than testing necessarily being refused.516
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Duncan et al. expressed concern about the lack of follow-up post-testing, particularly 
in the light of the limited evidence available on the effects of testing, and called for 
systematic follow-up after genetic testing of minors.517
Carrier testing and predictive genetic testing of minors is certainly happening, if 
not frequently in our own country (of which there is a dearth of evidence), then in 
others, despite the existence of professional guidance against testing of minors too 
young to give a valid consent. There is no reason to assume that carrier testing or 
predictive genetic testing of minors will not become more ubiquitous in New Zealand 
also once awareness, testing capability and resourcing increase, particularly as our 
genetics health professionals are governed by similar guidelines as professionals in 
other countries. 
.2  genetic testing of minors in new Zealand
There is very little evidence available regarding attitudes towards, and the practice 
of, predictive or carrier testing of minors in New Zealand. At this time, requests for 
predictive or carrier testing of minors are very rare.518 Genetic testing of minors 
currently proceeds on a case-by-case basis. Symptomatic genetic testing is commonly 
conducted and as discussed is rarely controversial. Testing for conditions for which 
medical interventions are available in childhood is also considered uncontroversial 
and warranted.519 
There are only six clinical geneticists in New Zealand. One clinical geneticist spoken 
to indicated that he had only ever received two requests for carrier testing of a child 
– in both cases it was for carrier testing of an adolescent (thirteen, fourteen years 
old). The geneticist spoken to indicated that the two cases were ‘very firmly in the 
grey zone’: there were rational arguments in favour of testing, but also reasons not 
to. One was earlier on in his career and he adhered strictly to the HGSA policy; there 
was no medical indication for testing, and the request came from the father, not the 
minor. 
The clinical geneticist spoken to had not received a request for a test from a competent 
minor. However, if the test were clinically advisable for whatever reason a competent 
minor would always be involved in the discussion and testing because he or she 
would need to give informed consent.520
The NHC commented in its 2003 Report, Molecular	Genetic	Testing	in	New	Zealand, 
that children and young people should be involved in such decisions, but that their best 
interests were ‘the bottom line’ and that testing for untreatable late-onset disorders 
may not be in their best interests. The NHC generally recommended against genetic 
testing of minors, except for conditions which had early onset or beneficial medical 
interventions available in childhood. 







comparatively	 few	patients,	 spends	considerable	time	on	each	one,	 is	research-
oriented,	and	places	extensive	emphasis	on	patient	education.521
The evidence of professional attitudes and practice in respect of genetic testing of 
minors is important because it shows that testing is occurring and that primary and 
secondary care health professionals are more willing than are geneticists to test for a 
wide variety of conditions. This is concerning because of the existing evidence that 
there are major gaps in the genetics knowledge of non-specialists. 
Primary and secondary care health professionals are apparently more willing to 
accede to parental requests for genetic testing of their children and more willing 
to provide all kinds of genetic tests, often regardless of whether or not the tests are 
clinically indicated.  
There is evidence that there are knowledge gaps in terms of primary health-care 
providers’ expertise with medical genetics; this is obviously troublesome if they are 
to be recommending or acceding to parental requests for genetic tests, and if they are 
to be involved in genetic counselling.
Genetic	 testing	 will	 enter	 clinical	 practice	 in	 many	 forms	 in	 the	 near	 future,	





Wertz’s survey of United States primary care physicians (499) found that, not only 
did they favour genetic testing more than geneticists, ‘but their knowledge of genetic 
disorders and the impact of these disorders on people’s lives may be woefully inadequate’. 
Only 58 per cent, for example, knew that HD was inherited in an autosomal dominant 
fashion; only 22 per cent knew that familial hypercholesterolaemia was autosomal 
dominant; 19 per cent thought that life expectancy with fragile X was less than twenty 
years; and 35 per cent thought that people with fragile X could not have children.523
Clarke cautioned that the differences of responses between the professional groups 
surveyed by the United Kingdom CGS likely reflected the different experiences of the 
professional groups.
2
...	The	 importance	of	 the	 survey	 result	 is	 that	 the	 sudden	availability	of	 these	




Another clinical geneticist (Harper) agreed, suggesting that differences between 
geneticists’ and other clinicians’ handling of HD testing perhaps reflects the fact that 
HD is known to be a genetic condition, and that clinical geneticists had seen it as 
part of their regular practice long before predictive tests were possible. Reflecting on 
troubling encounters ‘at-risk’ families had experienced with primary care physicians, 
he comments that ‘the situation will only improve when medical genetics and 
genetic counselling form an important part of medical education for all medical 
professionals’.525
Harper suggests that the availability of time may be a major factor in the difference 
between a genetic testing experience at a clinical genetics service, and an experience 
with a primary care physician. Communication, interactions and decision-making 
in the clinical genetics context can be very time-consuming, and can be repeated for 
years. 526 Harper argues that: 
…	at	present,	medical	genetics	services	are	structured	so	as	to	permit	this,	but	




The HGSA policy, Presymptomatic	and	Predictive	Testing	for	Genetic	Disorders	2005, 
acknowledges that, while clinical geneticists, genetic counsellors and many other 
health-care professionals are aware of the impact that such testing could have on 
individuals and families, ‘New groups of health professionals and potential test users 
need to become familiar with these tests and the context in which they are used’.
The American Academy of Pediatrics also supports ‘the expansion of educational 
opportunities in human genetics for medical students, residents, and practicing 
physicians and the expansion of training programs for genetic professionals.’528 
The	 increased	 availability	 of	 molecular	 genetic	 testing,	 coupled	 with	 the	
relatively	small	genetics	workforce,	is	expected	to	result	in	the	need	for	primary	
care	 physicians	 to	 become	 educated	 about	 the	 appropriate	 integration	 of	 such	
testing	 into	 their	 clinical	practice.	 In	particular,	because	as	many	as	one	 third	
of	 paediatric	 admissions	 are	 children	 with	 disorders	 with	 a	 genetic	 cause,	 it	





4.29.1  New Zealand
Similar concerns arise in New Zealand. 
Genetic	 testing	 technology	 has	 rapidly	 advanced	 and	 become	 more	 widely	





A 2002 Report for the NHC found that ‘currently in New Zealand a significant 
proportion of genetic tests are ordered by non-geneticsts’. The Report expressed 
concern that ‘lack of knowledge on the part of some non-genetic clinicians may impede 
the quality of services received by individuals outside specialist genetic services’.531
4.29.2  Surveys of GPs
The NHC survey of GPs in 2003 (discussed earlier) revealed that many GPs had little 
experience or knowledge of less common genetic conditions and displayed a lack of 
confidence about when to refer and to whom. Most of the respondents felt that they 
needed to know more about genetic testing to feel confident to deal with increasing 
public demand, including knowing when and for what conditions to refer a patient 
to genetics services, and how to discuss genetic tests and test results with patients.532 
Responses indicated that GPs tended to be more likely to refer patients to genetics 
services than to order genetic tests themselves. However, they were generally positive 
about getting involved in genetic testing as long as they had adequate resources and 
support.533
The rarity of the conditions made it particularly difficult for them to keep up with 
developments in knowledge and treatment of some heritable conditions.534 Some, 
particularly rural, GPs also found genetics services difficult to access. A smaller 
number also indicated that costs and waiting time could be a barrier to access to 
genetics services.535 
What	 is	 clear	 though	 is	 that	 a	 substantial	 number	 of	 New	 Zealand	 GPs	 are	
not	 sure	how	to	access	genetic	advice	 for	 their	patients	and	some	reported	not	
knowing	how	to	contact	Genetics	Services	in	their	locality.536
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The research with the GPs appears not have considered genetic testing of children in 
particular. However, one of the articles produced from the findings did note, in the 
context of considering predictive testing of children for myotonic dystrophy, that 
‘predictive testing would not be appropriate until they are at or above the age of 
consent (16 years in New Zealand)’.537 This implies that the authors, at least, accept 
that predictive testing (for a generally late-onset untreatable disorder) of minors who 
cannot give a valid consent is not appropriate in New Zealand. It further implies that 
minors aged sixteen years or over can consent to predictive testing for an untreatable 
disorder, as we argue later. 
The survey that Cameron et al. undertook also did not question respondents as 
to attitudes towards testing minors for increased susceptibility to breast cancer. 
However, they did note that ‘patients place considerable weight on the opinions of 
their doctors when making decisions about risk assessment procedures’. Thus their 
testing preferences were likely to be well established at the time of entry into the 
genetics services.538 
Given	that	many	individuals	are	referred	for	genetic	testing	by	their	GPs,	these	
practitioners	 play	 a	 pivotal	 role	 as	 de	 facto	 gatekeepers	 in	 the	 genetic	 testing	
process.	 ...	 Their	 views	 may	 determine	 whether	 they	 discuss	 genetic	 testing	
with	patients,	how	they	present	information	about	potential	consequences	and	
whether	they	encourage	or	discourage	testing.539
Interestingly, their survey results indicated that the GPs and the medical students held 
less favourable views about genetic testing than did the women’s groups (made up of 
patients recruited from the waiting rooms of seven clinics, breast cancer survivors and 
first-degree relatives of breast cancer survivors).540 The medical students were more 
cautious than the GPs about recommending genetic testing, and about expecting 
positive outcomes. GPs were more likely to emphasise the benefits of testing than the 
psychological costs, in their discussions with patients, whereas medical students gave 
the two topics more equal treatment.541
4.29.3  Paediatricians
Given their area of expertise and experience, paediatricians would be expected to know 
more than GPs and other groups of health professionals about genetics, genetic testing 
and genetics services in New Zealand. They would be expected to know more readily 
when and how to refer minors for genetic testing, as experts and also because they may 
be generally less isolated than some colleagues, based as they are within hospitals.
However, it is unclear to what degree pediatricians in New Zealand are aware of 
the HGSA policies (and the wider guidance and discourse) recommending against 
genetic testing of minors who cannot give a valid consent where there are no beneficial 
medical interventions available. 
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.0  Discussion 
The evidence and issues outlined raise significant concerns regarding the appropriate 
handling of genetic testing requests for minors, whether on behalf of those who 
cannot give a valid consent, or by competent minors themselves. 
The lack of knowledge amongst New Zealand GPs of genetics and of avenues for seeking 
further advice on genetic testing obviously has implications for the appropriateness of 
the ordering of genetic tests, and for informed consent processes.543 The NHC report 
emphasised the need for GPs to discuss more complex genetic testing (particularly 
predictive and susceptibility testing) with, or to refer to, a genetics specialist or 
service, because of their lack of experience and specialist knowledge of genetics.544 
This is particularly important in the case of genetic testing requests for minors, given 
the special care required during the informed consent process. 
The results of the research undertaken with New Zealand GPs are of particular 
concern in the light of the international evidence revealing greater willingness on the 
part of primary care health-care professionals to provide predictive genetic tests and 
carrier tests for minors. Without further investigation and evidence it is difficult to 
gauge whether our primary health-care professionals would be equally enthusiastic 
about genetic testing of minors. However, there is evidence that GPs are more likely 
to emphasise the benefits of susceptibility testing for BRCA mutations than the 
possible psychological harms.545 There is also evidence that New Zealand’s GPs are 
generally positive about getting involved in genetic testing decisions, if they are well 
resourced to do so.546 
More positively, the GPs surveyed appear to recognise their own limitations in terms 
of understanding clinical genetics, and currently seem to be more likely to refer 
patients to a genetics service than to order genetic tests themselves. 
It is vital that GPs and other health professionals know more about genetic testing 
and genetics services in New Zealand, so that they can better facilitate informed 
consent; recognise and acknowledge any limitations in their expertise, particularly as 
they will influence their patients when they discuss testing possibilities;547 know when 
to refer patients for genetic testing; and offer some degree of genetic counselling, 
if required. 
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A lack of genetic expertise and counselling is also of concern for competent minors 
seeking genetic tests because one of the important benefits of genetic testing upon a 
minor’s request is the chance for interaction with a knowledgeable health professional, 
rather than having to rely upon genetic information given by family members.548
Whilst there is some professional guidance on genetic testing of minors from the 
HGSA, and laboratory protocols on predictive testing generally, these do not appear 
to be well publicised or formalised. Pathologists involved in genetic testing would be 
aware of the HGSA guidance on genetic testing of minors.549 The oversight of genetic 
testing requests provides a useful filter for weeding out inappropriate testing of 
minors (and others); however, the ad	hoc basis upon which it is currently organised 
does not promote accountability. The lack of a more formal structure and process 
for genetic testing requests also means that GPs and other health professionals 
may be making inappropriate requests for testing that are (rightly) not actioned by 
pathologists, resulting in a waste of time and resources, and increased expectations 
and stress for at-risk families and children. 
GPs	 still	do	not	have	much	contact	with	genetic	 testing	and	 there	will	always	
be	problems	 training	groups	of	professionals	under	 these	circumstances.	 In	 the	
context	of	the	competing	demands	of	a	busy	general	practice	workload	GPs	need	
to	 know	 how	 to	 access	 information	 about	 Genetics	 Services	 easily	 when	 the	
need	arises.	GPs	who	responded	to	this	 survey	requested	access	 to	 information	
and	suggested	guidelines	and	continuing	medical	education	sessions	as	possible	
avenues	for	the	delivery	of	information.550
the next section of this report examines in detail the purported benefits  
and harms of genetic testing of minors, before examining how genetic  
testing decisions fit within the current legal framework for medical  
decision-making for children, and whether any differences are legally  
salient and require a different regulatory response.
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